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ABSTRACT
Polo-like Kinse 1 (PLK1) is a serine/threonine protein kinase that is expressed in
dividing cells. It is a widely studied protein that plays an important role in regulating
mitotic progression. PLK1 is over-expressed in several tumor types, and studies have
shown that down-regulating PLK1 expression inhibits cancer cell proliferation, validating
PLK1 as an oncotarget. Efforts to target this protein therapeutically has led to the
development of several ATP-based inhibitors, although these are not exclusively specific.
Because other PLK family members are tumor suppressors, it is important that PLK1
inhibitors selectively bind to PLK1 and not the other PLKs, particularly PLK3.
Moreover, resistance is always a problem with single agent therapies.

PLK1 is

comprised of two structural domains, the N-terminus catalytic kinase domain, and the Cterminus polo-box domain (PBD). The PBD is a phospho-peptide binding motif that
determines substrate recognition and sub-cellular localization. By targeting the PBD, we
can develop selective PLK1 inhibitors to inhibit cancer cell proliferation. REPLACE
(Replacement with Partial Ligand Alternatives for Computational Enrichment) uses the
structure activity relationships of peptide binding fragments to generate pharmaceutically
acceptable lead molecules. We began by replacing the N-terminus tripeptide sequence of
known PLK1 substrates like Cdc25C (LLCSpTPNGL) with molecular fragment mimics.
This generates partially peptidic compounds termed FLIPs (Fragment Ligated Inhibitory
Peptides). FLIPs were analyzed by fluorescence polarization (FP) to determine PLK1
and PLK3 PBD binding.

Our most promising FLIPs were analyzed in cellular
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assays. N-terminal FLIP SAR was also used to develop non-peptidic small molecules by
carrying out a compound library search. This led to the development and characterization
of more than 40 small molecules from a lead structure that was tested as part of a
structure activity relationship program. In summary, the work described advances our
understanding of the binding determinants for the PBD of PLK1 and produced lead
molecules worthy of further exploration in their ability to target PLK1 in cancer.
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CHAPTER ONE
INTRODUCTION
1.1 GENERAL OVERVIEW
Cancer is a disease of the genome. Research has revealed tumorigenesis to be a
multistep process resulting from genetic mutations that occur, leading to a gain of
function of oncogenes, and a loss of function of tumor suppressors. The processes that
drives the transformation of normal cells to a malignant state are considered the six
hallmarks of cancer. They include: 1) self-sufficiency in growth signals, 2) insensitivity
to growth-inhibitory signals, 3) evasion of programmed cell death, 4) limitless replicative
potential, 5) sustained angiogenesis, and 6) tissue invasion and metastasis (1). These
hallmarks acquired by cancer cells allow them to survive, proliferate, and disseminate
when they otherwise would not. Cancer cells are able to acquire these changes because
of two ‘enabling characteristics’ recently described by Hanahan and Weinberg (2011).
The two characteristics they describe are 1) the development of genomic instability in
cancer cells, and 2) immune system cells that drive the inflammatory state of
premalignant and malignant lesions. Genomic instability drives the random mutations
expressed in cancer cells while an inflammatory state promotes tumor progression by a
variety of ways (2). They also argue that two additional hallmarks contribute to the
development of cancer – the first being the reprogramming of cellular energy
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metabolism, and the second being the cancer cell’s avoidance from attack by immune
cells (2).

Normal cells tightly regulate cellular growth and division, and properly

maintain homeostasis of cell number through careful production and release of growthpromoting signals.

However, cancer cells deregulate this process resulting in an

overgrowth of cells (2).
It is well established that several kinases regulate the progression of both normal
and cancer cells through the cell cycle.

Polo-like kinases are a subfamily of

Serine/Threonine protein kinases that are involved in cell cycle regulation (3). This
family of kinases was first discovered during the 1980s through a series of genetic
screens in yeast (Cdc5), Xenopus (Plxs), Drosophila (polo), and mammals (PLKs). Pololike kinases are evolutionarily conserved, having a conserved N-terminal catalytic
domain – responsible for substrate phosphorylation; and a C-terminal polo-box domain
(PBD) – responsible for substrate recognition and binding (4).
Genetics studies in Drosophila and yeast indicated a variety of mitotic roles for
PLK1 in that mutants of Polo, CDC5, and PLO1 exhibited mitotic abnormalities and
spindle defects (5-7). It was in 1994 that human cDNAs (homologous to the Drosophila
polo gene) were cloned and named PLK (8). D. melanogaster, S. cerevisiae, and S.
pombe only have one PLK (Polo, Cdc5, Plo1, respectively), but vertebrate species have
several PLKs (9).
There are four mammalian PLKs functioning in cell cycle regulation including,
PLK1, PLK2 (a.k.a. SNK), PLK3 (a.k.a. PRK, FNK and CNK) and PLK4 (a.k.a. SAK).
PLK5, also a member of the PLK family, is not involved in cell cycle regulation and does
not have a functioning catalytic domain (10). PLK1 is the most widely studied among all
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PLK family members. Moreover, cell division was impaired in proliferating cells with
over- and under-expression of PLK1 (11, 12) – suggesting an important role PLK1 plays
in cell division of normal cells.
1.2 FUNCTION OF PLK FAMILY MEMBERS
PLK1
Polo-like kinase 1 (PLK1) is the most widely studied among all of the PLK family
members. It is only expressed in proliferating cells, having its maximum activity during
mitosis. PLK1 expression is low in G0, G1, and S, with expression beginning to rise in
G2, and peak in M phase (13-15).
Interphase
During interphase, PLK1 localization occurs at the cytoplasm and centrosomes
(16). Centrosome maturation occurs prior to mitosis and PLK1 regulates this process by
recruiting γ-tublin ring complexes (γ-TuRCs) to the centrosomes, and by phosphorylating
ninein-like protein (NLP) and translationally controlled tumor protein (TCTP) – proteins
involved in microtubule dynamics (17, 18). A mutation at the PLK1 phosphorylation site
within NLP results in improper formation of the mitotic spindle (18).
Synthesis (S Phase)
PLK1 is known for its role in mitosis, but studies have shown that PLK1
inhibition can slow DNA replication and even activate the DNA damage checkpoint,
suggesting a need for it in replication (19-21). PLK1 was shown to phosphorylate Hbo1
both in vitro and in cells at Ser-57 (19) . Hbo1 is responsible for facilitating the assembly
of the pre-replicative complex (pre-RC) on replication origins at the end of mitosis and
continuing through G1. Overexpressing mutant Hbo1 (S57A) at the PLK1
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phosphorylation site lead to G1/S cell cycle arrest, decreased the rate of DNA replication,
and inhibited chromain loading of the Mcm complex (19). It has been shown by coimmunoprecipitation that PLK1 and all members of the minichromosome maintenance
complex (Mcm2-7) bind (22). PLK1-dependent phosphorylation of Hbo1 is believed to
be necessary for pre-RC formation and DNA replication licensing, and is believed to
occur primarily at the end of mitosis (19).
Mitosis
PLK1 regulates mitotic entry (23), progression through mitosis (24-27),
cytokinesis (28), and is involved in mitotic exit (29). During mitosis, a cell’s genetic
material and its centrosomes are duplicated and equally distributed between the two
daughter cells that form to complete the process of cell division. In prophase, the
chromatin condenses and the nuclear envelope breaks down. During prometaphase, the
bipolar spindle forms, and in metaphase the chromosomes are aligned at the metaphase
plate and bound, via the kinetochores, to the microtubules.

The two sets of

chromosomes are separated during anaphase, and during telophase – the chromosomes
de-condense and two nuclei are formed. After this, cytokinesis takes place to seperate the
two daughter cells (30).
Mitotic Entry
PLK1 regulates the G2 to M phase transition through the mitosis promoting factor
(MPF) – a complex of cyclin-dependent kinase- 1 (CDK-1) and cyclin-B (31). During S
and G2 phase, CDK-1 is phosphorylated and cyclin B accumulates.

They form a

heterodimer resulting in a conformational change that activates CDK-1. WEE1 and
MYT1 are enzymes that phosphorylate and inhibit this complex. PLK1 is involved with
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cyclin B localization and WEE1 phosphorylation (32).

During G2, the MPF is

dephosphorylated by Cdc25C – a phosphatase that is a substrate of PLK1 – activating the
MPF. This activation is what causes mitotic entry (33). PLK1 recognizes a specific
sequence on Cdc25C and binds to it during prophase. Once bound by PLK1, Cdc25C is
translocated to the nucleus allowing it to be phosphorylated and activated by PLK1 (32).
PLK1’s involvement in mitotic entry has been clearly documented, however, PLK1’s role
is not essential because PLK1 depleted cells are still able to enter mitosis. Problems arise
as these cell progress through mitosis (34).
Mitotic Progression
PLK1 promotes mitotic entry, although its primary role is to regulate mitotic
progression and exit (7, 35, 36). Once a cell enters mitosis the centrosomes migrate to
opposite poles to form the spindles needed for cell division. During mitosis, PLK1
localizes to the centrosomes, kinetochores, and equatorial spindle mid-zone (37, 38).
Bipolar spindle formation does not occur when PLK1 is inhibited by RNAi or small
molecules, resulting in monopolar spindle formation and prometaphase arrest (39). In
addition, kinetochores fail to properly attach to microtubules upon PLK1 depletion (16,
40).
PLK1 plays a vital role in the metaphase to anaphase transition, in that it helps to
regulate chromosome alignment at the metaphase plate.

PLK1 localizes to the

kinetochores where it provides stability by creating tension between the kinetochores and
microtubules (34). To transition from metaphase to anaphase PLK1 phosphorylates
EMI1, resulting in its inactivation.

This allows the anaphase promoting

complex/cyclosome (APC/C) to become activated (41).
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During telophase PLK1 localizes to the mid-zone and mid-body (42). Studies
have shown that cells overexpressing PLK1 are multinucleated, indicating that
appropriate PLK1 levels are necessary for proper completion of cytokinesis (11). In
addition, studies have shown PLK1 phosphorylation of Golgi-associated protein
GRASP65, leads to Golgi stack fragmentation. This also suggests an indirect role of
PLK1 in cytokinesis via Golgi-associated proteins, since many of the proteins that
dissociate from the Golgi during fragmentation help to regulate cytokinesis (43).
Therapeutic Target
Efforts to target PLK1 therapeutically are due to its over-expression in a number
of cancers including colorectal, prostate, and non-small cell lung cancer (44-46). Overexpression of PLK1 correlates to poor prognosis in some cancers (3, 47, 48). Many ATPcompetitive inhibitors have been developed, and some have advanced to clinical trials;
however, these inhibitors are not selective for PLK1 and target other kinases. Because the
catalytic domain is highly conserved among all kinases, it is important to target a noncatalytic domain of PLK1 to achieve selectivity. PLK1 is a unique target for drug
development in that, due to its highly conserved domains, there are two target sites within
the molecule that have differing functions and properties (discussed later) (3).
PLK2
PLK2 (SNK; serum inducible kinase) was first identified as an early-growth
response gene having a role in early mitogenic response (49), but was later found to be
involved in centriole duplication and cell proliferation (50-53). There is also evidence
suggesting PLK2 is a tumor suppressor, being downregulated in a variety of cancer cells
(54, 55).
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PLK2 expression and activity increases as cells enter S phase (49, 53), localizing
to the centrosomes. Although studies have shown that PLK2 inhibition leads to an
aberrant number of centrioles (50, 51, 56), PLK2 is not believed to be essential due to the
viability of PLK2 knockout mice (53).

PLK2 transcripts are expressed in both

proliferative and non-proliferative tissues, including the testis, mammary gland, spleen,
uterus, trachea and cardiomyocytes. PLK proteins are known for their role in the cell
cycle, but PLK2 is also expressed in the central nervous system – playing a role in
synaptic homeostasis and neuronal differentiation. It is expressed in the cerebral cortex,
hippocampus, occipital, temporal and parietal lobes, putamen and trigeminal ganglion,
and it is minimally expressed at the cerebellum (4). PLK2 is also involved in neuronal
cell differentiation (57). PLK2 levels are significantly increased in the brains of patients
with Alzheimer’s and Lewy Body disease (58).
There is high sequence homology between PLK1 and PLK2. There is nearly 50%
homology between their kinase domains and about 30% homology between their PBD’s,
however, PLK1 and PLK2 have opposing functions in tumor development (59).
PLK3
PLK3 (Fnk or Prk) was first identified as an early response gene product (60, 61),
and was later shown to regulate mitosis and DNA damage response (62-64). PLK3
protein levels are constant throughout the cell cycle, having increased mRNA levels
during G1 (61, 65), and kinase activity peaking during late S and G2 (66, 67). PLK3
localizes to the nucleolus (68), centrosomes, spindles, microtubules (66, 69), and the
Golgi apparatus where it is involved in regulating golgi dynamics (70).

During

interphase, PLK3 localizes around the nuclear membrane (66). PLK3 is required for
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transition from G1 to S phase, through interacting with Cdc25A and indirectly impacting
cycle E accumulation (68). PLK3 becomes phosphorylated and activated when a cell is
stressed due to DNA damage. When this occurs, PLK3 binds to and activates p53 (65),
resulting in p53 stabilization (63).
Gene expression studies show that PLK3 levels are decreased in tumors (71),
while overexpression inhibits cellular growth (72).

PLK3- deficient mice develop

tumors, suggesting that is protein acts as a tumor suppressor (72). Ectopic expression of
PLK3 disturbs microtubule integrity, causes G2/M arrest, and leads to apoptosis (66, 73).
In addition, PTEN – a known tumor suppressor – is a substrate of PLK3 (74). Taken
together, these results confirm PLK3’s role as a tumor suppressor.
PLK4
PLK4 (SAK) is the most divergent PLK family member, having a C-terminus that
contains only one polo-box. It is not believed to function as a binding domain. Instead it
functions as a homo-dimerization domain (75).

PLK4 expression increases during

mitosis and has been shown to be an important regulator of centriole duplication in both
Drosophila and mammals (76-79). Overexpressing SAK/PLK4 in Drosophila embryos
induced centriole amplification (76). Altered PLK4 levels results in irregularities in
centriole biogenesis and cell division. This leads to mitotic disruptions and aneuploidy
(80). Specifically, downregulation of PLK4 in Drosophila results in a loss of centrioles
leading to the formation of disorganized spindle poles (78, 79, 81). PLK4 has been
shown to interact with proteins involved in cell proliferation including p53 (82) and
Cdc25C (83).
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PLK5
PLK5 is the most recently identified PLK family member. It has a stop codon
within the catalytic domain and is highly expressed in the central nervous system. PLK5
is only expressed in non-proliferative tissues and is mostly transcribed in the cerebellum
(84). PLK5 is also in the cytoplasm of neurons and glia. PLK5 over-expression results
in G1 cell cycle arrest (84). Hyper-methylation and silencing of PLK5 was observed in
human brain tumors at the mRNA and protein level.

Re-expressing PLK5 in this

environment resulted in kinase-dependent apoptosis. Taken together, this suggests that
PLK5 may function as a tumor suppressor in the brain (84). PLK5 was also implicated in
DNA damage responses (85).
1.3 PLK1 AS VALID THERAPEUTIC TARGET
Many mitotic proteins have been targeted for cancer therapeutic development (30,
86, 87), and anti-mitotic drugs have proven to be valid and effective anticancer therapies
(88). PLK1 is only expressed in proliferating cells (11) and, as previously stated, PLK1 is
over-expressed in many cancers, including – breast, colorectal, non-small cell lung
cancer, prostate, pancreatic, papillary thyroid, ovarian, Non-Hodgkins lymphoma, and
head and neck cancer (71, 89-93). Overexpression has been associated with poor
prognosis and lower survival rates (48, 91, 94). In fact, the Kaplan-Meier-Plotter online
tool was used to create a survival plot for patients with lung and gastric cancer based on
PLK1 expression (95). This meta-analysis based biomarker assessment shows decreased
patient survival when tumors overexpress PLK1 in lung and gastric cancers (Figure 1.1).
PLK1 has been evaluated as an anti-cancer therapeutic target because of the
critical role that PLK1 plays throughout the cell cycle (86).
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PLK1 is a valid

chemotherapeutic target and many PLK1 inhibitors have been developed and evaluated in
preclinical and clinical studies (3, 88, 96).
PLK1 AND ITS ROLE IN CANCER
PLK1 promotes the proliferation of both normal and cancer cells. However, when
PLK1 is mutated or over-expressed, mitotic cell cycle checkpoints are bypassed, leading
to tumorigenesis. PLK1 is overexpressed in many cancers, including breast, ovarian, and
colorectal, and its over-expression correlates with poor prognosis in some cancers (97).
Microinjected PLK1 mRNA into quiescent NIH 3T3 cells induced cell cycle progression
from G0 to mitosis. In addition, constitutively expressed PLK1 in NIH 3T3 cells resulted
in anchorage-independent growth of cells in soft agar and tumor formation in nude mice
(12). Moreover, elevated PLK1 mRNA levels have been detected in numerous tumor
types (3).
Tumor suppressors like p53 (98) and PTEN (74) , and oncogenes like Kras (99)
are frequently mutated in cancer.

Synthetic lethality has been demonstrated when

knocking down or inhibiting PLK1 in cancer cells lacking p53, expressing Kras
mutations, or when PTEN deficient.

The following section briefly discusses the

interaction between PLK1 and p53, Kras, and PTEN.
PLK1 and p53:
p53 is a tumor suppressor that is involved in many important cellular processes
including differentiation, senescence, cell cycle arrest, DNA repair, inhibition of
angiogenesis, and apoptosis (100). p53 induced cell cycle arrest allows for DNA repair
or recovery to occur prior to replication events. This process prevents the replication of
damaged DNA.

If damage is too extensive and repair cannot occur, p53 induced
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programmed cell death occurs. This process prevents tumorigenesis in normal cells, but
very often cancer cells have lost p53 function.
The association between p53 and PLK1 has been confirmed by many studies.
These proteins negatively regulate each other in that p53 stability increased in PLK1
deficient HeLa cells while p53 levels remained low in PLK1 proficient HeLa control
cells (36).

PLK1 interacts with p53, inhibiting transcription and proapoptotic

mechanisms (101, 102). In addition, p53 depleted cancer cells are more sensitive to
PLK1 loss than p53 proficient cells (102).
PLK1 and Kras:
The Ras family of GTPases are responsible for transmitting proliferative signals
from membrane growth factor receptors to the cell nucleus.

Numerous tumors –

including lung, liver, and colon – have been found to express KRAS mutations (103).
Efforts to develop drugs that target Ras were marginal therefore, studies were carried out
to determine what synthetic lethal interactions exist in cancers expressing mutant KRAS
(99). Results showed that Ras mutant cells were sensitive to knockdown of mitotic genes
(99). More specifically, mutant Ras tumor cells were found to be more sensitive than
wild-type cells when PLK1 was knocked down by siRNA or inhibited by BI-2536. In
addition, the cellular phenotypes of these cells were consistent with mitotic stress,
including prometaphase cell cycle arrest. It was suggested that Ras mutations led to
increased mitotic stress. This in turn causes the cells to have a greater dependence on
PLK1 for mitotic progression (99).
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PLK1 and PTEN:
PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a tumor
suppressor that negatively regulates the PI3K/Akt pathway by removing a phosphate
group from phosphoinositide 3,4,5-trisphosphate, blocking the recruitment and activation
of PKB/Akt kinases responsible for signal transduction (104). Loss of PTEN function
leads to excessive signaling of this pathway and promotes tumorigenesis (105). PTEN is
a substrate of PLK3 and it is phosphorylated by PLK3 at Thr-366 and Ser-370. Xu et. al.
(2010) showed that PLK3-mediated phosphorylation regulates PTEN stability (74).
PTEN is also involved in mitosis, playing a role in PLK1 degradation and helping to
facilitate centromere integrity (106, 107). PTEN depleted prostate cancer cells have
elevated PLK1 expression and undergo mitotic stress. PLK1 was shown to play an
important role in the survival of PTEN depleted cancer cells. PTEN depleted cells were
more sensitive to PLK1 inhibition compared to wild-type cells, and underwent greater
levels of apoptosis (108).
Taken together, this information validates PLK1 as a feasible oncotarget. Several
ATP-based inhibitors of PLK1 have been developed as potential therapeutics, and some
have reached clinical trials. Non-ATP-competitive inhibitors have also been developed.
The section below will summarize information for some of the PLK1 inhibitors found in
literature.
1.4 CATALYTIC INHIBITORS OF PLK1
BI2536
BI 2536 (developed by Boehringer Ingelheim Pharma, Ingelheim, Germany) is a
small molecule inhibitor of PLK1 that works by targeting the catalytic domain via the
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ATP-binding site. This molecule has a sub-nanomolar binding affinity to PLK1 in vitro
and was shown to be 1000-fold more selective for PLK1 compared to other kinases,
however, it does also inhibit the function of PLK2, PLK3, and PLK4 (109). This drug
has been studied in cancer cells, providing valuable insight into the effects of PLK1
inhibition.

Cells treated with BI2536 experienced prometaphase arrest, lacked

microtubule asters, and formed monopolar spindles (110). BI2536 also prevented
localization of PLK1 to the centrosomes and kinetochores. Studies with this drug indicate
that PLK1 is not necessary for entry into prophase, but it does cause cells to accumulate
in prophase, delaying entry into prometaphase (16). Anti-tumor activity was also
observed in xenograft mouse models of human cancer (93), with side effects occurring in
the bone marrow and other organs with high cell proliferation (111).
BI2536 entered phase I and II clinical trials where the activity and safety of BI2536 in patients with a variety of advanced tumors – including head and neck, breast,
ovarian, soft tissue sarcoma, and melanoma, were examined. BI-2536 was well tolerated,
with neutropaenia and thrombocytopenia being the primary adverse side effect, but they
observed insufficient anti-tumor activity due to poor pharmacokinetics (110, 112-114).
Additionally, its potency toward PLK3 might account for its poor anti-tumor effects since
PLK3 has opposing functions to PLK1.
BI6727
BI6727 (Volasertib) is a second-generation drug from BI2536 (115). Although it
is a potent PLK1 inhibitor (IC50 of 0.87 nM), it also has an affinity for two other PLK
family members – PLK2 (IC50 of 5 nM) and PLK3 (IC50 of 56 nM). Like BI2536, this
compound works by targeting the catalytic domain. It binds to the ATP- binding pocket
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and causes monopolar spindles to form (116). This compound was found to be active
against many cancer cell lines, with cell proliferation EC50 values between 10-40 nM. It
was also shown to be effective in human cancer xenograft models (116). The sensitivity
of colorectal tumor cells to BI6727 was found to be independent of p53 status, however,
cells having defective p53 experienced a greater incidence of multipolar spindles. It is
suggested that this is because cells having wild-type p53 undergo apoptosis, while p53defective cells undergo cell cycle arrest in mitosis with multipolar spindles (117).
BI6727 advanced to clinical trials (118, 119), and was well tolerated in patients.
Like BI2536, phase I clinical trials determined that the most common side effects were
neutropenia or thrombocytopenia, but the conditions were treatable and reversible.
BI6727 also demonstrated favorable pharmacology having a MTD of 400 mg and a halflife of 110 hours. The anti-tumor activity was also encouraging, being effective in
patients that had poor responses with other treatments (111). BI6727 progressed to phase
II clinical trials and was granted breakthrough status by the FDA after significant results
were observed when used in combination with cytarabine for Acute Myeloid Leukemia
treatment.
GSK461364A
GSK461364A is another catalytic inhibitor that was developed by Glaxo Smith
Kline (Middlesex, UK) (120, 121). It inhibits PLK1 with a Ki of 2.2 nM and is 390-fold
more selective for PLK1 over PLK2, and 1000-fold selective for PLK1 than PLK3.
When compared to other PLK1 inhibitors that have also reached clinical trials,
GSK461364A shows greater specificity to PLK1 then to other PLKs.

GSK461364

induced mitotic arrest is concentration dependent, with concentrations >300 nM causing a
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delay in G2. Concentrations ranging between 10-30 nM induced mitotic arrest which led
to severe micronucleation and cell death. Concentrations < 10 nM resulted in modest
mitotic effects and moderate cytokinesis inhibition (122).
This compound was shown to be active against many cancer cell lines (123). Cell
lines having non-functional p53 were shown to be most sensitive to PLK1 inhibition,
however phenotypic results in lung and pancreatic tumor cell lines suggested a p53
independent effect. Following treatment with this catalytic inhibitor, phenotypic results
showed that both Cyclin B1 and phospho-histone H3 levels accumulated, and mitotic
slippage occurred (123). In vivo studies investigating the efficacy of this compound in
preventing brain metastases of breast cancer showed that it was successful in inhibiting
brain metastases by 60% in a xenograft model system (124).
Phase 1 clinical trials were carried out in patients with advanced solid
malignancies (125). These patients were split into two groups that were administered the
drug once a week (schedule A) or two times a week (schedule B). PLK1 was effectively
targeted in tumors, however, thromboembolism occurred twenty percent of the time, with
mild hematologic toxicity also taking place. Eighteen percent of patients developed
neutropenia. This is a significant improvement from the 45% of patients that developed
neutropenia in the BI 2536 clinical trial (125). The overall best response of stable disease
(>16 weeks) occurred in 15% of patients. Although GSK461364 targeted PLK1 and antitumor activity it was recommended to be used in conjunction with a prophylactic
anticoagulant (125).
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GW843682X
GW843682X – a derivative of GSK461364A – causes mitotic arrest, spindle
defects, and aberrant cytokinesis – phenotypes that are consistently observed with
catalytic inhibition of PLK1 (120). Lung adenocarcinoma (H460) cells displayed aberrant
mitotic events, including multipolar spindle formation, underwent cell cycle arrest, and
died via mitotic catastrophe following treatment with this compound (120).
TAK-960
TAK-960 was developed by Takeda Pharmaceuticals. It binds to PLK1, PLK2,
and PLK3 to varying degrees (IC50 = 0.8 nM, 17 nM, 50 nM, respectively). Cell cycle
analysis results in HT-29 cells showed an accumulation of cells in G2/M phase following
treatment with TAK-960. Fluorescence microscopy results showed monopolar spindle
formation and increased levels of phosopho-histone H3 (126). Anti-proliferative activity
was shown to be p53 independent in a panel of 18 cell lines. In addition, a reduction in
tumor volume was observed in 10 xenograft mouse models (126). This compound is
currently in clinical trials.
ZK-THIAZOLIDINONE
Like the previously mentioned catalytic PLK1 inhibitors, ZK-Thiazolidinone
(TAL; Bayer Schering Pharma AG, Berlin, Germany) prevents the proliferative activity
of a number of cancer cell lines, causes G2/M arrest, increases phosphoHistone-H3
levels, and causes cell death by mitotic catastrophe (91). In addition, TAL treatment
resulted in monopolar spindle formation, impaired recruitment of γ-tublin to the
centrosomes, and failed completion of cytokinesis (91). TAL also impaired recruitment
of Aurora A kinase to the centrosomes.
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ON 01910.Na
ON 01910.Na is a small molecule that was developed by Onconova Therapeutics.
It inhibits PLK1 in substrate-dependent and ATP-independent manner (127).

This

compound primarily active against PLK1 but it is not selective, inhibiting other kinases
like PLK2. ON 01910.Na causes mitotic arrest, induces multipolar spindles, causes
abnormal centrosome localization and fragmentation, chromosome misalignment and
detachment from spindles. These aberrant mitotic events leads to apoptosis (127). ON
01910.Na was active against many cancer cell lines, including drug-resistant cell lines. It
also showed activity in vivo as a single agent, and when used in combination with other
therapies like paclitaxel, vincristine, and doxorubicin (127).
ON 01910.Na went through phase I trials. Twenty patients having solid tumors
were administered the drug at two hour infusions. It was determined that the maximum
tolerated dose was 3120mg with skeletal and abdominal toxicity.

Patients also

experienced nausea and fatigue. Overall, ON 01910.Na was found to show moderate
toxicity (128).
HMN-214
HMN-214 is an oral prodrug of HMN-176 with cytotoxic effects against several
tumor types (89). HMN-176 indirectly inhibits PLK1 by altering is spatial distribution.
This leads to cell cycle arrest, destruction of spindles, and DNA fragmentation (89, 129,
130). HMN-176 was active against a verity of human tumors in vivo, demonstrating
antitumor activity in an exposure-dependent manner.

HMN-214 in vivo antitumor

activity was found to be comparable or greater to that of known anti-cancer agents like
doxorubicin (89, 130).
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HMN-214 was tested in phase I clinical trials to determine its phramacokinetic
properties. HMN-214 was found to be rapidly converted to HMN-176 and patients
developed neutropenia with modest anti-tumor activity (89, 130).
1.5 NON-ATP COMPETITIVE PBD INHIBITORS OF PLK1
POLOXIN
Poloxin was the first small molecule shown to bind to the polo-box domain (PBD)
in vitro, by fluorescence polarization assay, and in cancer cells (131). This compound is
a non-peptidic inhibitor of PLK1, having an IC50 value of 4.8 μM. Poloxin also binds to
the PBD of PLK2 and PLK3 with IC50 values of 18.7 μM and 53.9 μM, respectively. It
displays anti-proliferative activity in a variety of cancer cell lines with IC 50 values
ranging between 15-35 μM (132). Mitotic phenotypes associated with Poloxin treatment
were found to include mislocalization of PLK1, fragmented and dissociated centrosomes,
abnormal mitotic spindles, and misaligned chromosomes at the metaphase plate (132).
These defects resulted in mitotic catastrophe leading to apoptosis.

Unlike catalytic

inhibitors that caused mono and multipolar spindle formation, bipolar spindles were
present upon treatment with Poloxin (132).
More recently an optimized analogue of Poloxin, Poloxin-2, has been shown to
have increased potency and selectivity over Poloxin.

It induces mitotic arrest and

apoptosis in human cancer cells at low micromolar concentrations, and is a promising
candidate for future studies in cancer cells (133).
PURPUROGALLIN (PPG)
Purpurogallin (PPG) is a small molecule identified by high-throughput screening
that binds to PLK1 with an IC50 value of 0.3 μM (134).
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PPG-treated HeLa cells

displayed reduced PLK1 locatization to the centrosomes and kinetochores, and cell
accumulation in G2/M. Consistent with Poloxin – another PBD inibitor – PPG did not
induce monopolar spindle formation.
1.6 OUR APPROACH TO TARGETING THE POLO-BOX DOMAIN (PBD)
PLK1 is just one of more than 500 protein kinases contained in the human
proteome (135). This fact only emphasizes the complexity involved in developing a
selective PLK1-inhibitor. While catalytic inhibitors have proven potent, there is still an
issue of selectivity. Due to the non-selective attributes of catalytic inhibitors, there are
off-target affects that cause dangerous clinical side effects. The kinase domain of the
PLK family members contain many of the conserved features of other protein kinases,
and they are highly similar to one another. This makes it difficult for most catalytic
inhibitors to discriminate between the PLK family members (136).

The catalytic

domains of PLK2 and PLK3 are most alike while PLK1 and PLK4 are least alike (135,
137, 138).
There is an additional challenge when considering intracellular ATP
concentrations. ATP is typically at a millimolar concentration within a cell, making it
difficult to develop a small molecule that can compete for the ATP-binding site. To
develop a useful ATP-inhibitor, the compound must be both selective and have a high
binding affinity.
Because many ATP- competitive inhibitors have issues with specificity (139),
there are efforts to develop inhibitors that target different domains. The Polo-box domain
(PBD) is a highly conserved C-terminal domain among PLK family members. It is a
phospho-dependent docking motif that brings the protein – having a phospho-threonine
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or phospho-serine – into close proximity to its substrates (140). Structural analysis of the
two polo-boxes (PB) that form the PBD were shown to have similar tertiary structures.
The boxes fold together and form the interface for ligand binding (140). The PBD serves
a regulatory function in that when the PB is bound to the kinase domain, it blocks the
docking site within the kinase domain. When the PBs (forming the PBD) are bound to
their phosphoprotein substrate, the PBD releases from the kinase domain, allowing it to
bind to its target substrate (11, 141, 142).
Overexpressing the PLK1-PBD domain causes mitotic arrest and abnormal
spindle formation (143). Catalytic activity of PLK1 also decreases when peptides bind to
the PBD (144). Additionally, there are significant structural and functional differences
between the PBD’s of the PLK family members (145). Taken together, this suggests that
PBD-inhibition could mimic the phenotypes observed with ATP-inhibition and provide
significant target selectivity (86).
Lastly, a recent chemical genetics study has demonstrated that cells containing a
single point mutation within the ATP-binding site of PLK1 (C67V) are resistant to
several structurally unrelated ATP-inhibitors, while retaining the catalytic activity for its
substrates (146). Such a mutation is likely to be observed clinically, eventually rendering
the ATP-inhibitors ineffective. For these reasons, it is important to take an alternative
approach in targeting PLK1 in cancer cells.

We are interested in developing non-

catalytic PBD-inhibitors to selectively target PLK1 to avoid off-target side effects that
result from non-selective ATP-inhibition and to circumvent resistance observed with
catalytic inhibitors.
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REPLACE METHOD
This study examined the use of a systematic approach to examine the structure
activity relationship (SAR) of peptide inhibitors to generate pharmaceutically acceptable
small molecules. REPLACE (Replacement with Partial Ligand Alternatives through
Computational Enrichment) uses the SAR of known peptide inhibitors to generate lead
molecules. Individual amino acid residues – or groups of amino acid residues – from
truncated substrate peptides were replaced with non-peptidic small molecular fragments.
This is a structure guided drug discovery process that is a validated and more cost
effective alternative to high-throughput screening (147, 148).
We exploit the truncated phosphopeptide sequence of known PLK1 substrates
Cdc25C (LLCSpTPNGL) and PBIP (PLSHpTAI) (140, 149, 150).

These truncated

peptides are known to selectively bind to the PBD of PLK1. Although peptides are nondrug like, they are able to discriminate between the PLK family members. We can
exploit the substrate selective differences of these peptides to develop selective PLK1
inhibitors (147).
We used the REPLACE method to determine the structure activity relationship of
the sequence, and replace portions of the peptide – starting with the N-terminal fragment
(LLC) – with small molecule fragments.

The most promising partially peptidic

molecules (FLIPs; Fragment Ligated Inhibitory Peptides) will be synthesized and tested
biochemically to determine potency and selectivity for PLK1. The most promising FLIPs
will then be tested in cells to determine activity and mechanism of action.
A biochemical and cellular analysis of truncated peptides and FLIPs will be
discussed in Chapter 3. Here we analyze binding to PLK1-PBD and determine the
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selectivity relative to PLK3-PBD. For the most promising FLIPs, we measure efficacy in
cancer cell lines. Chapter 4 will discuss PLK1-PBD and PLK3-PBD binding of small
molecule (non-petidic) PLK1 inhibitors synthesized by Dr. Sandra Craig (McInnes Lab).
In addition, cellular analysis PBD-inhibitors will also be discussed.

The overall

conclusions, clinical implications of these findings, and the future directions of this work
will be discussed in Chapter 5.
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FIGURES

Figure 1.1 Kaplan Meier survival curve analysis of PLK1expression. Plots were
generated using KM-plotter’s online analysis software. Gene expression and clinical data
from >1900 lung and >870 gastric cancer patients were split into two cohorts and
compared by a Kaplan-Meier survival plot.
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CHAPTER TWO
RE-OPTIMIZING THE PLK1 AND PLK3 POLO BOX DOMAIN (PBD)
COMPETITIVE BINDING FLUORESCENCE POLARIZATION (FP) ASSAY
ABSTRACT
The fluorescence polarization (FP) assay is a competitive binding assay that we
use as our primary screen to measure compound binding to PLK1 and PLK3. We began
using low volume 384 well plates to reduce the amount of reagents used per assay. As a
result, new assay conditions had to be determined to accurately measure binding. This
chapter explains the process by which PLK1 and PLK3 FP assay conditions were
determined for optimum detection by the plate reader.
2.1 INTRODUCTION
We determined the relative affinities of peptides, Fragment Ligated Inhibitory
Peptides (FLIPs) and compounds for the PBD of PLK1 and PLK3 using a fluorescence
polarization (FP) assay. This is a competitive binding assay that allows us to indirectly
measure compound binding by quantifying the compound’s ability to displace a
fluorescein labelled tracer peptide from its PBD binding site. This is an equilibrium
reaction with the equation:

When tracer molecules are unbound to the PBD protein, they freely rotate in
solution resulting in low fluorescence polarization. Conversely, PBD-bound tracer rotates
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slowly in solution and yields high fluorescence polarization values. Polarization values
are generated from parallel and perpendicular fluorescence intensities.
The inhibitor will compete with the fluorescein tracer for PBD binding, displacing
it from the PBD if it has an affinity for the protein. We are able to ‘visualize’ this
competition by measuring the polarization of bound tracer relative to unbound tracer.

Therefore, to accurately measure binding the assay conditions must be properly
optimized for optimum detection. First, the tracer concentration must be selected that
provides an excellent signal to noise ratio and does not saturate detection limits. Next, the
concentration of fluorescent tracer is held constant and a concentration curve with the
PBD protein must be analyzed to determine the concentration at which at least 80% of
the tracer is bound to the PBD.

Once the proper concentrations are determined,

increasing concentrations of the compound can be added to the reaction, and compound
binding affinity for the PBD can be determined by measuring fluorescence polarization in
millipolarization (mP) units (1).
The FP assay is our primary screen to determine the binding affinity of our
compounds to the PBD of PLK1 and PLK3. Molecules of interest are quantitated by a
reduction in millipolarization (mP) values that occur as the tracer is displaced from the
PBD, and plotted as an IC50. The 2012 MCT paper (2) details the results of the first
utilization of this assay on the prior series of peptides and FLIPs that formed the starting
point of this thesis. During the course of this work, the assay conditions were further
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optimized as part of a regular quality control process and after switching to low-volume
384-well plates to save on reagents. This chapter explains the process to optimize the FP
assay and discusses why this process is so important for accurately measuring binding
affinity.
2.2 METHODS
Optimization of Fluorescence for the Peptide Tracer
To determine the optimal tracer concentration that provides excellent signal to
noise ratio without saturating the detection signal, a tracer titration curve was carried out.
Increasing concentration (0.1 – 300 nM) of tracer was added to the 384 well plate in
triplicate. Because the concentration will be diluted by one-third once all solutions are
added to the well, tracer was made up at a concentration 3 times the desired final
concentration, such that 0.1 nM final concentration was made up at 0.3 nM concentration.
Dilutions were made using a BSA containing buffer (10 mM Tris HCl pH 8, 1.0 mg/mL
BSA). 5 µL tracer was added to each well along with 10 µL of 1X buffer (50 mM Tris
HCl, 200 mM NaCl, 0.005% Tween, 20 mM DTT). 1X buffer is used to dilute the PBD
protein in a typical FP assay.

The plate was then spun down using a centrifuge

(Eppendorf 5804 R) and analyzed for fluorescence values using the Beckman Coulter
DTX 880 multimode detector plate reader.
PBD Protein Optimization
After confirming the appropriate fluorescent tracer concentration needed for the
assay (typically no less than 10-fold signal above background) (1), a protein dilution
curve was carried out. Briefly, using a 384 well plate, 5 µL of tracer was added to the
appropriate wells, keeping the concentration constant.

39

Increasing concentration (0.5

ng/well – 250 ng/well) of PBD protein was also added to the 384 well plate in triplicate.
PBD protein dilutions were made using a 1X buffer (50 mM Tris HCl, 200 mM NaCl,
0.005% Tween, 20 mM DTT). The plate was then spun down using a centrifuge
(Eppendorf 5804 R), incubated on a shaker at room temperature for 45 minutes, and spun
down once more before analyzing using the Beckman Coulter DTX 880 multimode
detector and multimode analysis software.

Binding was measured by calculating

millipolarization (mP) values. The optimum PBD concentration was determined to be
when 90% of the fluorescent tracer was bound (EC90).
Determining the Dissociation Constant (Kd)
Fluorescence polarization, in millipolarizaton (mP) units, was measured at an
excitation wavelength of 488 nm and an emission wavelength of 535 nm, using the DTX
880 plate reader and multimode analysis software (Beckman Coulter). We determined
the

dissociation

constant

(Kd)

of

the

PLK1

fluorescent

tracer

(MAGPMQS[pT]PLNGAKK) to the PLK1 PBD (amino acids 367-603) and PLK3
fluorescent tracer (GPLATS[pT]PKNG) to the PLK3 PBD (amino acids 335-646). A Kd
measurement for the PBD of PLK3 was determined in order to establish a counter
screening assay. This allows us to accurately determine the selectivity of our compounds
for PLK1 relative to PLK3.
2.3 RESULTS
PLK1 and PLK3 Fluorescent Peptide Titration Curve
Using the raw fluorescent values, a fold fluorescent curve was plotted for the
PLK1 and PLK3 tracer dilutions.

It is recommended to use the concentration that

provides at least 10-fold signal above background (1), however, the concentration
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equivalent to 10-fold fluorescent signal (~0.1 nM) was not sufficient for detecting
binding when doing the protein dilution curve.

We determined that a 10 nM

concentration provided a strong fluorescent signal and we went on to use this
concentration for the PLK1 and PLK3 PBD binding curves (Figure 2.1 and 2.2).
PLK1 PBD Binding Curve
We used a 612 nM concentration of PLK1 PBD (250 ng/well) under previous
assay conditions. We determined that 41.4 nM (17 ng/well) of PLK1 PBD should be
used in the re-optimized FP assay. This represents the concentration at which 90% of the
tracer is bound to the PBD (Figure 2.3).
PLK3 PBD Binding Curve
Under previous assay conditions we used PLK3 PBD at 487.4 nM (250 ng/well).
New assay conditions require 245 nM (125.6 ng/well) to be used. This concentration
represents 90% binding of the tracer to the PBD (Figure 2.4).
Fold Selectivity
The PLK1 PBD fluorescent tracer binds to the PLK1 PBD with a Kd of 4.6 nM
(Figure 2.3), while the PLK3 PBD fluorescent tracer binds to its PBD with a Kd of 27.2
nM (Figure 2.4). The PLK1 fluorescent tracer binds with a ~ 5-fold higher affinity to its
PBD. This difference in binding affinity is taken into account when calculating the fold
selectivity index of our compounds.
2.4 DISCUSSION
We began using low volume 384 well plates to analyze the binding affinity of our
compounds to the PBD of PLK1 or PLK3. In doing so, the volume contained in the wells
(15µL) were brought much closer to the PMT detector of the plate reader, thereby
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increasing the intensity of the fluorescence signal being read by the plate reader. Using
the tracer concentration from previous FP assay conditions (100 nM) caused signal
saturation in the low volume plates. As a result, we re-optimized the assay conditions by
determining the new concentration of fluorescent peptide, and the concentration of PBD
protein needed when using low volume 384 well plates.
Upon switching to low volume 384 well plates (Greiner Bio-one), we determined
from fluorescent tracer titration curves that the tracer concentration could be reduced 10fold yet maintained optimum fluorescent signal. The PLK1 and PLK3 tracer could be
used at 10 nM, therefore working stocks of each tracer peptide was made up at a 30 µM
concentration and stored at -20˚C. We found that 30 µM tracer stocks could undergo 5-7
freeze – thaw cycles before the fluorescent signal began to weaken, presumably because
of degradation. When the signal weakens we are no longer able to accurately detect PBD
binding, so the stock was discarded after 5 – 7 uses.
Under prior assay conditions the PLK1 and PLK3 PBD was used at a 250 ng/well
(50 ng/ µL) concentration. New protein dilution curves were used to calculate the
concentration of PBD needed for the competition assay in which 90% of the tracer is
bound. Optimized assay conditions revealed that the PLK1 PBD could now be used at a
17 ng/well (3.4 ng/µL) concentration and the PLK3 PBD concentration at 125 ng/well
(25 ng/µL).
Importance of Quality Control Processes
Although new assay conditions have been determined, it is important to confirm
the assay conditions by repeating a tracer titration curve and PBD binding curve anytime
a new stock or lot of PBD protein or fluorescent tracer is used. The FP assay is a
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competitive binding assay that allows for an indirect measure of compound binding to the
PBD by measuring the polarized fluorescence of bound tracer relative to unbound tracer.
In other words, we are able to measure the binding affinity of our compounds to the PBD
of PLK1 and PLK3 by measuring the displacement of the tracer molecule from the PBD,
because the compounds are competing for the same binding site.
If too high a concentration of tracer is used relative to PBD protein, the signal
from the unbound excess tracer will saturate the detection limits of the machine. This, in
turn, results in an inaccurate measure of the binding affinity of a compound.
Also, too low of a tracer concentration relative to PBD protein will result in an
underestimation of compound binding. We are only able to detect a compound’s binding
affinity by measuring the displacement of the tracer molecule from the binding site. An
excess of unbound PBD protein leads to an underestimation of compound binding
because the compound will bind to the excess PBD without displacing a tracer molecule.
Therefore, more compound will be needed to detect binding, resulting in an inaccurately
high IC50 value.
Note that, as part of this process, several key peptides and FLIPs originally
published in the 2012 MCT paper (2) were re-tested in the FP assays optimized for 384
well low volume plates. In the subsequent chapters, the values for these previously tested
peptides and FLIPs are from the more newly optimized assay. These values are more
appropriately (directly) compared to the IC50 values of all peptides, FLIPs, and nonFLIPs in the following chapters, which are all determined in the low volume plate assays.
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FIGURES

Figure 2.1 PLK1 tracer dilution curve and fold-fluorescence tracer curve

Figure 2.2 PLK3 tracer dilution curve and fold-fluorescence tracer curve
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Figure 2.3 PLK1 PBD dilution curve. The dissociation constant (Kd = 4.6 nM) and
EC90 (41.1 nM) was determined from the curve.
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Figure 2.4 PLK3 PBD dilution curve. The dissociation constant (Kd = 27.2 nM) and
EC90 (245 nM) was determined from the curve.
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CHAPTER THREE
BIOCHEMICAL AND CELLULAR ANALYSIS OF PEPTIDES AND FLIPS*
ABSTRACT
Polo-like Kinase 1 (PLK1) performs critical roles in the coordination of mitosis
and is also an oncogene over-expressed in many cancer types.

ATP-binding site

inhibitors of PLK1 have progressed to clinical trials, and one was recently given FDA
breakthrough status to treat acute myeloid leukemia. However, recent data suggests that
there are major disadvantages to blocking the kinase activity of PLK1.

We have

validated the innovative REPLACE strategy by discovering non-ATP competitive and
PLK1-selective inhibitors as an alternative therapeutic strategy for this important target.
The Polo-box domain (PBD) of each PLK is a phospho-peptide binding motif that
determines substrate recognition and subcellular localization. Our approach targets the
PBD of PLK1 to achieve desired selectivity and improve efficacy. Through modeling and
design we produced a series of fragment-ligated inhibitory peptides (FLIPs). We report
three FLIPs with an octyl-benzamide group, having the following different amino acid Cterminus sequences: -PNGL, -AI, and –PL. In vitro binding to the PBDs of PLK1 and
PLK3 was measured by a fluorescence polarization assay. The IC50 values for PLK1
calculated from the competition assay are 0.36 μM, 0.41 μM, and 1.2 μM, respectively,
and all three are at least >1800-fold more selective for PLK1 compared to PLK3. Initial
*

Merissa Baxter, Sandra Craig, Michael D. Wyatt, Campbell McInnes. 2016. In
preparation for submission.
47

testing in two cancer lines revealed respectable anti-proliferative activity for two of the
FLIPs. In addition, we report the investigation of our PBD-inhibitors in cells expressing
the mutant C67V PLK1 that is resistant to ATP-based inhibitors. We find that our
compounds are equally active in cells expressing wild-type or C67V PLK1, whereas cells
expressing C67V PLK1 are dramatically resistant to the ATP-based inhibitor, BI 2536.
These exciting developments demonstrate the validity of our approach to produce druglike lead PBD-inhibitors that are PLK1 selective and are active against tumors resistant to
ATP-inhibitors. PBD-inhibitors could ultimately be used in combination therapy
regimens with ATP-based inhibitors for a dual attack on this important, clinically
validated oncology target.
3.1 INTRODUCTION
The polo-like kinases are central players in regulating entry into and progression
through mitosis (1). A significant body of literature has determined that profound antiproliferative activity is achieved through selective inhibition of PLK1 functions (2). The
four known human PLKs have non-redundant and non-overlapping functions.
Overexpression of PLK1 is frequently observed and PLK1 expression is a prognostic
indicator for outcome of patients suffering from various tumors (3-5). More than half of
prostate cancers overexpress PLK1 and this expression is positively correlated with
tumor grade (6). PLK1 is extensively overexpressed in colorectal cancer (7) and recently
was demonstrated to be a potential therapeutic target in such tumors with inactivated p53
(8). Moreover, it has been reported that p53 transcriptionally regulates PLK1 expression,
providing direct evidence that PLK1 is oncogenic when p53 is mutated (9). Thus, there
is a strong rationale for pursuing PLK1 as an anti-tumor drug target. Indeed, the
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therapeutic rationale for PLK inhibition has been validated through several studies and
shown to profoundly inhibit cancer cell proliferation both in vitro and in vivo (10, 11).
Numerous inhibitors of the ATP-binding site of PLKs have been identified, with some
entering clinical trials after showing significant anti-tumor activity in preclinical models.
At least two compounds have been evaluated in phase I clinical trials. Results from two
compounds suggest acceptable toxicity profiles warranting further investigation in phase
II trials (12, 13). Recently BI6727 (volasertib) was granted FDA breakthrough therapy
designation for Acute Myeloid Leukemia. Unfortunately, however, there are numerous
drawbacks to targeting the ATP cleft, including prominently the inhibition of the 3 other
known members of the mammalian PLKs (14). Because PLK3 has been reported to have
opposing functions to PLK1, PLK3 inhibition may lead to diminution of the anti-tumor
effect mediated by blocking PLK1 (15-17). These issues were revealed after the initial
clinical development of ATP-competitive PLK inhibitors and strongly suggest that
inhibiting PLK3 would not a desirable feature of a clinical candidate. In addition, ATP
competitive inhibitors will only block the enzymatic functions of PLK1 and will not
necessarily affect its critical non-catalytic functions. Therefore, alternative approaches to
develop potent and highly selective PLK1 inhibitors are required. Studies with peptides
provide evidence that the substrate and sub-cellular targeting binding site in the Polo Box
Domain (PBD) forms a compact and druggable interface amenable to small molecule
inhibitor development (18-21). Although high-throughput screening approaches have
identified small molecule inhibitors of the PBD-peptide interaction, these either are
weakly binding or non-drug-like in nature (22, 23). In addition, these inhibitors display a
contrasting phenotype to PLK1 knockdown and to cellular treatment with inhibitors of
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catalytic activity (14, 24, 25). Recently progress has been reported in the generation of
derivatized peptides that occupy a novel site in the PBD binding groove (26, 27).
Peptides, while also non-drug-like, can discriminate between the PLK family
members and can therefore provide a structural basis for the development of selective
PLK1 inhibitory compounds. Herein, REPLACE, a validated strategy for the iterative
discovery of non-peptidic protein-protein interaction inhibitors, has been applied to
discover fragment alternatives for the N-terminal hydrophobic motif in a Cdc25C PBD
substrate peptide. Furthermore, using transfected PBD binding peptides and Fragment
Ligated Inhibitory Peptides (FLIPs), a workflow for phenotypic and PLK1 specific
cellular effects has been established. Results demonstrate that PBD-targeted inhibitors
replicate a PLK1 phenotype, in contrast to the partial phenotype obtained with PBD
dominant negative and small molecule inhibitors, suggesting that they inhibit both
subcellular localization and substrate phosphorylation.
3.2 MATERIALS AND METHODS
Peptide and FLIP Synthesis
The McInnes group generated fragment ligated inhibitory peptides (FLIPs) and
small molecule (non-peptidic) inhibitors through a validated strategy called REPLACE
(Replacement with Partial Ligand Alternatives through Computational Enrichment). This
is a computational and synthetic approach that uses structure activity relationships of
peptide inhibitors to generate pharmaceutically acceptable lead molecules. Fragments are
docked into the crystal structure of a truncated peptide/receptor complex, synthesized,
and subsequently tested in an in vitro binding assay. While retaining the peptide core
structure, the N-terminal tripeptide sequence was removed and replaced by molecular
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fragments that mimic the binding contributions of the amino acids in the PBD binding
pocket. Replacing both the N and C- terminal peptide sequences with small molecular
fragments generate small molecules.
Fluorescence Polarization Assay
FLIPs and peptides to be tested were dissolved in DMSO (10 mM), and diluted
from 600 µM (maximum of 6% DMSO tolerance in the assay) to 10 nM. The PLK1 PBD
(367-603) and PLK3 PBD (335-646) proteins were obtained from BPS Bioscience Inc.
(San Diego, CA); 17 ng

PLK1

and 156 ng PLK3 were used per reaction.

The

fluorescein-tracer phospho-peptides (MAGPMQS[pT]PLNGAKK for PLK1, and
GPLATS[pT]PKNG for PLK3) were used at a final concentration of 10 nM. Incubation
was carried out at room temperature for 45 minutes while shaking. Fluorescence was
measured using a DTX 880 plate reader and Multimode Analysis software (Beckman
Coulter, Brea, CA).

The polarization values in millipolarization (mP) units were

measured at an excitation wavelength of 488 nm and an emission wavelength of 535 nm.
Each data point was performed in triplicate for every experiment, and experiments were
performed at least three times. An IC50 value for each compound was calculated from
linear regression analysis of the plots.
PLK1 Kinase Inhibition Assay
The CycLex™ Polo-like kinase 1 Assay/Inhibitor Screening Kit was used to
measure catalytic inhibition of peptides and FLIPs (CycLex Co, Ltd., Nagano, Japan).
This ELISA assay measures the catalytic activity of full length PLK1 for a defined
substrate, which is detected by an anti-phospho-threonine antibody (PPT-07) and
peroxidase coupled secondary antibody. Plates pre-coated with a Threonine containing
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substrate were incubated with PLK1, kinase buffer containing 7.5 µM ATP (modification
from recommended concentration), in the absence or presence of increasing
concentration of peptides or FLIP molecules. After incubation, the phosphorylated
substrate resulting from PLK1 kinase activity was detected using the PPT-07 antibody,
and horseradish peroxidase conjugated anti-rabbit IgG antibody. Peroxidase catalyzes
the conversion of the colorless solution to yellow, which was quantified using a DTX 880
plate reader. Absorbance measurements (450 nm) were plotted to calculate activity in
each sample, and % inhibition was calculated in the FLIP containing wells relative to
activity in the absence of inhibitor.
Cell Culture
HeLa cervical cancer cells were obtained from ATCC (Manassas, VA) and were
not authenticated by the authors for this study. Histone H2B GFP-labeled HeLa cells
(HeLa-H2B-GFP) were kindly provided by Dr. Geoffrey Wahl (Gene Expression
Laboratory, Salk Institute) [29], and were confirmed as >95% GFP positive by FACS
(data not shown) but were not otherwise authenticated. Cells were maintained in DMEM
(Invitrogen, Carlsebad, CA) supplemented with 10% FBS or Nu-serum (BD Bioscience,
Franklin Lakes, NJ) and 1% penicillin/streptomycin (Invitrogen) in a humidified
incubator and 5% CO2 at 37°C.
PC3 prostate cancer cells were kindly provided by Dr. Shafiq Khan (Clark Atlanta
University, Atlanta, GA) and were not authenticated by the authors for this study. Cells
were maintained in DMEM (Invitrogen, Carlsebad, CA) supplemented with 10% FBS or
Nu-serum (BD Bioscience, Franklin Lakes, NJ) and 1% penicillin/streptomycin
(Invitrogen) in a humidified incubator and 5% CO2 at 37°C.
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A-549 lung cancer cells were obtained from ATCC (Manassas, VA) and were not
authenticated by the authors for this study. Cells were maintained in Hams F-12 1X with
glutamine (Cellgro, Manassas, VA), and supplemented with 10% FBS or Nu-serum (BD
Bioscience, Franklin Lakes, NJ) and 1% penicillin/streptomycin (Invitrogen) in a
humidified incubator and 5% CO2 at 37°C.
Retinal Pigment Epithelial (RPE) cells were kindly provided by Dr. Prasad V.
Jallepalli (Memorial Sloan-Kettering Cancer Center, New York, NY) Cells were
maintained in 1:1 DMEM/Hams F-12 (Invitrogen, Carlsebad, CA; Cellgro, Manassas,
VA), and supplemented with 10% FBS or Nu-serum (BD Bioscience, Franklin Lakes,
NJ) and 1% penicillin/streptomycin (Invitrogen) in a humidified incubator and 5% CO2 at
37°C.
Cell Viability Assay
Exponentially growing cells were plated in 96- well dishes. Dose response curves
were used to treat cells for 72 hours with FLIPs. Following the three-day treatment, cell
viability

was

measured

using

the

MTT

(3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide) colorimetric assay. Cells were incubated for 3 hours with
MTT allowing viable cells to metabolize the tetrazolium dye to a purple colored solution.
Absorbance measurements (595 nm) were quantified using a DTX 880 plate reader and
IC50 values were generated for FLIPs.
Serum Starved Cell Synchronization
Cells were synchronized in G1 by serum starvation.
growing

cells

were

plated

overnight.

Media

Briefly, exponentially

(DMEM,

10%

FBS,

1%

penicillin/streptomycin) was then removed and replaced with serum free media for 72
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hours. Cell were subsequently treated for 24 hours with FLIP inhibitors. Following
treatment, cells were collected, fixed with 70% ethanol, and processed by flow
cytometry.
3.3 RESULTS
Structure-activity relationship of peptidic inhibitors for the polo-box domains of PLK1
and PLK3.
Initially, a titration curve of the PLK1 and PLK3 PBDs with their respective
fluorescent tracers was performed to determine a Kd value (binding affinity). The PLK1
PBD fluorescent tracer binds to the PLK1 PBD with a Kd of 4.6 nM (Chapter 2, Figure
2.3), while the PLK3 PBD fluorescent tracer binds to its PBD with a Kd of 27.2 nM
(Chapter 2, Figure 2.4). These curves were also used to calculate the concentration of
PBD for the competition assay in which 90% of the tracer is bound. The PLK1
fluorescent tracer binds with a 5- fold better affinity to its PBD, which is taken into
account to calculate a fold selectivity index.
The peptide structures were designed to probe the contributions of the N- and Cterminal residues of the recognition sequences from Cdc25c (LLCSpTPNGL) and PBIP
(PLHSpTAI) (18-20), two known substrates of PLK1. The affinities of the peptides and
FLIPs for PLK1 or PLK3 were measured by plotting the loss of polarization against
increasing concentration of competitor peptide. C-terminal truncations were previously
shown to retain binding affinity to PLK1 (28). We also showed that acetylation of the Nterminal Pro positively contributes to binding (28). The results in Table 3.1 shows that
combining portions of the two naturally occurring substrates created a peptide (5987) that
bound with high affinity (IC50 = 0.06 ± 0.04 µM) for PLK1. Importantly, these peptides
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retain strong selectivity for PLK1 over PLK3 (Fold Selectivity >13,000). We also
examined 5902, which is the consensus recognition sequence for PLK3 reported in the
literature (22). Interestingly, 5902 has a high affinity for the PLK1 PBD (IC50 = 0.0057 ±
0.002 µM), higher than that seen for PLK3 (PLK3 IC50 = 2.2 µM). However, it should be
pointed out that 5902 and 6023, with the N-terminal GPLATS sequence, possess
significant affinity for PLK3 compared to the other peptides with the N-terminal PLHS
sequence (Table 3.1).
Optimization of 4-alkylbenzamido N-cap and truncation studies on residues C-terminal to
the phosphothreonine.
Our previous report identified an N-terminal benzamide capping group with an
alkyl tail as a promising starting structure, and identified a butyl-benzoic containing FLIP
(5827) with low µM affinity for the PLK1 PBD and undetectable binding to PLK3 (28).
FLIPs containing N-terminal benzamide capping groups with increasing length of alkyl
tail were designed to exploit a hydrophobic pocket in the PBD of PLK1 (Table 3.2).
With FLIPs containing the C-terminal portion of the Cdc25c sequence (PNGL), a clear
structure activity relationship (SAR) was observed with lengthening the alkyl tail from
butyl (5827), to hexyl (5956), then octyl (5954), and improved affinity to PLK1 (IC50 =
2.5 ± 0.96; 1.06 ± 0.51; 0.36 ± 0.16 µM, respectively) while maintaining excellent
selectivity. Although 5954 (octylbenzoic-FLIP) measurably bound to the PBD of PLK3,
it remains over 2000-fold more selective for PLK1 (Table 3.2).
Based on the results from the PNGL FLIPs, C-terminal modifications were
explored with the octyl-benzamide FLIPs (Table 3.3). When the C-terminal PNGL
sequence was replaced with alanine, the resulting FLIP (5988) bound to the PLK1 PBD
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with a 42-fold weaker affinity (comparing 5954, 0.36 ± 0.16 µM to 5988, 15.2 ± 4.74
µM). Although PLK3 binding (IC50 = 201.9 µM) also decreased, it was not by as much,
which dramatically reduced the selectivity (compare >2400-fold selectivity to 66-fold
selectivity). Adding an isoleucine to the alanine (5996) improved PLK1 PBD binding
(IC50 = 0.41 ± 0.14 µM) by 37-fold relative to 5988, while only marginally changing
PLK3 binding (IC50 = 152.8 µM). This substantially improved selectivity. When the Cterminus was replaced with proline and leucine, the resulting FLIP (6026) bound to the
PLK1 PBD with a 3-fold weaker affinity (IC50 = 1.2 ± 0.18 µM), compared to 5996 but
remained selective for PLK1 (Table 3.3). These results indicate the importance of the Cterminal interactions in PLK1 affinity and selectivity. Future iterations of REPLACE are
focused on C-terminal substitutions with drug like structures that retain PLK1 binding.
Select FLIPs were also tested in a commercially available in vitro kinase assay
that utilizes full-length PLK1 (Materials and Methods). We tested BI-2536 in the assay at
a range of ATP concentrations up to 50 µM (the manufacturer’s recommended
concentration) and observed a decrease inhibition with increasing ATP concentration as
is expected for a competitive inhibitor. Utilizing an ATP concentration of 7.5 µM
reported by Steegmaier et al in their characterization of BI-2536 (25), we calculated for
BI-2536 an IC50 value of 2.8 nM (not shown), which is within good range of the prior
report but ~3-fold lower. Table 3.2 and Table 3.3 shows that the FLIPs (5954, 5996,
6026) tested can inhibit the catalytic activity of PLK1, demonstrating that targeting the
PBD can inhibit substrate recognition and kinase activity.

56

PLK1-inhibition by FLIPs is synthetic lethal with PLK1 and PTEN deficient or mutant
Ras cancer cells
Cell viability was measured to determine the anti-proliferative activity of 5996
and 6026 (Table 3.4). Despite their peptidic composition, the FLIPs possessed modest
cellular activity with no delivery agent. The IC50 of 5996 in HeLa cells was 128.1 μM.
PTEN deficient prostate cancer (PC3) cells and Kras mutant (A-549) lung cancers cells
also showed sensitivity to PLK1 inhibition. While 6026 possessed cellular activity in
Hela cells is it less potent than 5996 so its effect in PC3 and A-549 cells was less
dramatic relative to 5996. These results are consistent with the concept that inhibiting
PLK1 is synthetic lethal with PLK1 and PTEN deficient or mutant Ras cancer cells
(Table 3.4).
Targeting the Polo-Box Domain of PLK1 circumvents resistance to catalytic inhibitors in
cells expressing mutant (C67V) PLK1
Burkard et al. showed that a single point mutation (C67V) within the ATPbinding domain of PLK1 confers resistance to several structurally unrelated ATP-binding
site inhibitors, including BI-2536 (29). We obtained the RPE cells generated by the
Burkard group and confirmed the resistant phenotype by cell viability assay (Table 3.5).
Our results confirm that WT RPE cells are sensitive to BI-2536 (IC50 = 21.2 nM) while
mutant RPE cells are dramatically resistant to BI-2536 (> 2.5 µM). The PBD-targeted
FLIPs are growth inhibitory in the PLK1 C67V mutant-expressing cells that are resistant
to catalytic inhibitors (Table 3.5).
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G2/M Cell Cycle Arrest
PLK1 catalytic inhibition induces prometaphase arrest (14, 30, 31), and we have
previously demonstrated that PBD- inhibition induces a consistent mitotic phenotype
(28). Here we show that synchronized (G1) PC3 cells treated for 24 hours with 6026
accumulate in G2/M. G1 arrest is observed when the cells are treated using a higher
dose, which suggests off target or additional effects (Table 3.6; Figure 3.1).
3.4 DISCUSSION
Our goal was to build on the finding of our previous study (28) and further
explore the development of PBD- inhibitors of PLK1 through the use of REPLACE. By
exploiting the protein-protein interactions of known substrates we applied the REPLACE
method to discover new fragment alternatives for the N-terminal hydrophobic motif of
Cdc25C and PBIP. In addition, we characterized the efficacy of these inhibitors and
determined their mechanism of action. Our results demonstrate that PBD- targeted PLK1
inhibitors can be developed through REPLACE. Peptide structures were probed to
determine the N- and C-terminal contributions within the PBD binding pocket. Although
peptides are not useful drug molecules, the SAR helped to identify important residues for
substrate binding and selectivity. These amino acid contributions were used to generate
FLIP molecules and can be further explored and used to develop non-peptidic drug-like
small molecules.
We previously reported the importance of N-terminal acetylation to improve the
binding affinity of peptides for the PLK1 PBD (28). Here we report acetylated PIBP
binding to PLK1 with an IC50 = 0.064 µM (6025). Although there is measureable
binding to PLK3, 6025 is more than 20,000 fold more selective for PLK1. Removal of
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the isoleucine from the C-terminus of this sequence resulted in a 7-fold decrease in PLK1
binding (compare 6025 to 5743). This suggests an important contribution of isoleucine in
the binding pocket of PLK1 PBD. A decrease in PLK3 binding was also observed, further
suggesting that isoleucine is contributing to PLK1 selectivity. Removal of the N-terminal
proline from 6025 (and acetylated leucine, 5781) results in an even greater loss of
binding to PLK1 (~24-fold).
Combining the amino acid sequences of two substrates (N-terminal sequence of
PBIP with C-terminal sequence of Cdc25C) led to one of our most promising peptide
inhibitors (5987) – having high affinity and selectivity for PLK1. After it was determined
that 5902, the consensus recognition sequence for PLK3, was more selective for PLK1,
we combined the acetylated N-terminal amino acid sequence of PBIP (5743) with the Cterminal amino acid sequence of 5902. This also resulted in a structure (6024) with high
affinity and selectivity for PLK1.

Differences in C-terminal amino acid sequence

between 5902 and 6023 (compare -PNGL with -PKNG) resulted in modest differences in
PLK3 binding, suggesting the C-terminus is playing a greater role in PLK1 selectivity.
Further study of the C-terminal SAR could provide more insight into generating a PLK1
selective small molecule.
We previously report an N-terminal benzamide capping group with an alkyl tail as
a promising starting structure for the development of PBD-inhibitors. We identified a
butyl-benzoic containing FLIP (5827) with low µM affinity for the PLK1 PBD and
undetectable binding to the PLK3 PBD (28). We observed increased binding to the
PLK1 PBD with lengthening the alkyl tail, however PLK1 selectivity was reduced due to
measurable PLK3 PBD binding. We also observed measurable catalytic inhibition with
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5954. This demonstrates that targeting the PBD not only inhibits substrate recognition,
but it also interferes with the catalytic function of the protein.
We went on to develop FLIPs to investigate the C-terminal amino acid
contributions to the PBD binding pocket by replacing the –PNGL sequence with alanine
(5988). We observed a decrease in PLK1 PBD binding and an even greater decrease in
PLK1 selectivity. Upon the addition of an isoleucine (5996), PLK1 binding increased
relative to 5988, while PLK3 binding changed moderately, resulting in a substantial
increase in PLK1 selectivity. Lastly, we replaced the C-terminal amino acids with –PL
(6026).

While this change only moderately impacted PLK1 binding, we observed

decreased binding to PLK3, thereby further increasing PLK1 selectivity. Taken together,
these results suggests that the C-terminal amino acids do contribute more to PLK1
selectivity – as previously suggested from the peptide SAR – while the N-terminal amino
acids contribute more significantly to PLK1 binding affinity. Future studies should
further explore C-terminal SAR and develop molecular fragment replacements that
mimic the amino acid contributions.
Peptides are typically not effective drugs due to their poor permeability and
stability. However, we were able to measure cellular activity with our most potent
FLIPs, 5996 and 6026. These compounds are believed to be cell permeable due to the
hydrophobic alkyl tail. Although partially peptidic, we observed a measurable decrease in
cellular proliferation without the use of a drug delivery agent. Literature indicates a
synthetic lethal interaction between PLK1 and PTEN deficient and Kras mutant cancer
cells (32-34).

Our results are consistent with these findings when treating PTEN
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deficient PC3 and Kras mutant A-549 lung cancer cells with 5996. PC3 and A-549
cancer cells were also sensitive to PLK1 inhibition.
Cell having a single point mutation (C67V) within the catalytic domain of PLK1
were greater than 110-fold more resistant to inhibition with BI-2536 than cells expressing
wild type PLK1 (Table 3.3). These results are consistent with the study by Burkard et al
(29). We have demonstrated that both wild type and mutant (C67) PLK1 expressing cells
are sensitive to PBD inhibition. This is a very encouraging result because the issue of
resistance is always a concern with cancer therapeutics. Future studies could explore the
effectiveness of combination therapy using ATP-based and PBD-targeted inhibitors.
This study further validates the use of the REPLACE method to develop small
molecule PBD-inhibitors. Our PBD inhibitors have a high binding affinity for PLK1 and
are also selective for PLK1. Through REPLACE we have identified a promising druglike molecular fragment that replaces the three N-terminal amino acids of the original
peptide sequence (Cdc25C; -LLC). In addition, we have identified the importance of the
C-terminal contacts that contribute to PLK1 binding and selectivity. Moreover, despite
their peptidic composition, our FLIPs inhibit the catalytic activity of PLK1, are active in
a cell viability assay, and circumvent resistance to ATP-based inhibitors observed in
mutant PLK1 cells. Future studies should further explore the potency of our PBD
inhibitors in several cancer cells models using a drug delivery system. Although the
FLIPs were permeable, a drug delivery system will allow for a more efficacy, and better
studies of on target activity in cells. One approach is to develop a prodrug. This would
protect the amino acids until the compound penetrates the cell membrane and is
metabolized to its active form. Additionally, a continued study of the C-terminal SAR
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would provide additional insight into the binding contributions of the C-terminal amino
acids. This information could then be used with REPLACE to generate acceptable lead
molecular fragments as we work toward developing a non-peptidic small molecule.
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Table 3.1 Structure Activity Relationship of Peptidic Inhibitors. Values indicate
binding affinity for PLK1 and PLK3. PLK1 selectivity is also indicated.
SCCP
ID#

PLK3
IC50
[μM]
>600

Selectivity
Index

LLCS[pT]PNGL

PLK1
IC50
[μM]
0.17 ± 0.03

Sequence

292
293

LLCSTPNGL

>600

ND

ND

5743

Ac-PLHS[pT]A

0.46 ± 0.12

>600

>6500

5987

0.06 ± 0.04

163.6

13,633

6025

AcPLHS[pT]PNGL
Ac-PLHS[pT]AI

0.064 ± 0.01

270.5

21,133

5781

Ac-LHS[pT]AI

1.57± 0.47

>600

>1900

5902

GPLATS[pT]PKNG

0.0057 ± 0.002

2.2

1928

6023

GPLATS[pT]PNGL

0.011 ± 0.003

6.3

2864

6024

AcPLHS[pT]PKNG

0.032 ± 0.012

133.8

20,906
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>17,000

Table 3.2 Biochemical Analysis of FLIP Inhibitors with N-terminal benzamide
capping group. Compound structure, binding affinities, PLK1 selectivity, and catalytic
inhibition are indicated.

Table 3.3 Biochemical analysis of octyl-benzamide FLIP Inhibitors. Compound
structure, binding affinities, PLK1 selectivity, and catalytic inhibition are indicated.
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Table 3.4 Anti-proliferative activity in PTEN deficient and Kras mutant cancer
cells. Values were generated from three independent cell proliferation experiments.

Table 3.5 Anti-proliferative activity in mutant PLK1 Retinal Pigment Epithelial
(RPE) cells. Values were generated from three independent cell proliferation
experiments
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Table 3.6 Cell Cycle Analysis of PC3 cells. Cells were treated with 6026 (24 hours)
after being serum starved (SS) for 72 hours. The untreated group represents SS cells (72
hours) and released into drug free media (24 hours). Numbers are bold and underlined to
emphasize cell cycle population comparisons.
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FIGURES

Figure 3.1. Cell cycle analysis of PC3 cells following 24 hour treatment with 6026.
Cell were synchronized in G1 by 72 hour serum starvation before treatment. Untreated
cells were serum starved then released into drug free media for 24 hours.
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CHAPTER FOUR
BIOCHEMICAL AND CELLULAR ANALYSIS OF SMALL MOLECULE INHIBITORS*
ABSTRACT
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in cell
cycle regulation and mitotic progression. Studies have shown that PLK1 is upregulated
in several tumors, and in some cases its overexpression is adversely related to prognosis.
Studies have also shown synthetic lethality knocking down or inhibiting PLK1 in PTEN
deficient prostate tumors and in Kras mutant colorectal tumors, further validating PLK1
as an oncotarget. PLK1 is comprised of two structural domains. The highly conserved
kinase domain, and the Polo-Box Domain (PBD). The PBD is phospho-peptide binding
motif that is responsible for substrate recognition and binding, and subcellular
localization. An effort to target this protein therapeutically has led to the development of
several ATP-binding site inhibitors, some of which have advanced to clinical trials.
However, there is concern about the selectivity of these compounds for PLK1, as these
inhibitors have been shown to inhibit three of the four PLK family members. This is
problematic because PLK3 has been shown to act as a tumor suppressor. Moreover, it
has been shown that a point mutation in PLK1 (C67V) confers dramatic resistances to
ATP-binding site inhibitors. An alternative approach to developing potent and selective
PLK1 inhibitors is to target the PBD. Through our validated REPLACE strategy we have

*
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preparation for submission.
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developed PLK1 inhibitors that target the PBD.

We report the structure activity

relationship (SAR) of our first generation small molecules. In vitro binding to the PBDs
of PLK1 and PLK3 was measured by fluorescence polarization (FP) assay, and we
confirmed PLK1 binding in an orthogonal in vitro ELISA based PLK1 kinase assay. We
also demonstrate that our compounds inhibit cancer cell proliferation and are effective in
cells expressing mutant (C67V) PLK1.
4.1 INTRODUCTION
Polo-like kinase 1 (PLK1) is a mitotic protein that is only expressed in dividing
cells (1). It plays an important role in cell cycle regulation and mitotic progression (2-4).
PLK1 is overexpressed in a number of tumors (5-9), and its over-expression correlates
with poor prognosis in some cancers (10-12). In addition, studies have demonstrated a
synthetic lethal interaction when knocking down or inhibiting PLK1 in Pten deficient
prostate tumors and Kras mutant colorectal tumors (13-15). Studies have also shown that
inhibiting PLK1 expression results in cancer cell death, further validating PLK1 as an
oncotarget.
PLK1 is comprised of two structural domains (16). The catalytic kinase domain
is highly conserved among PLK family members, and is the target site of many catalytic
inhibitors – several of which have advanced to clinical trials (17-22). The polo-box
domain (PBD) of each PLK is a phospho-peptide binding motif that is responsible for
substrate recognition and sub-cellular localization (23).

Although several catalytic

inhibitors have advanced to clinical trials, there is concern about the selectivity of these
compounds for PLK1.

ATP-based compounds inhibit three of the four known

mammalian PLKs to various degrees (24-26).
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This is problematic because PLK3

functions as a tumor suppressor, therefore inhibiting its activity could counteract the
antitumor effect of blocking PLK1. Moreover, a recent study demonstrates that a single
point mutation within the catalytic domain of PLK1 (C67V) confers dramatic resistance
to several structurally unrelated ATP-binding site inhibitors (27). Such a mutation is
likely to be observed clinically, eventually rendering the ATP-inhibitors ineffective.
An alternative approach to developing potent and selective PLK1 inhibitors is to
target the PBD. While the PBD is a conserved domain among PLK family members,
each PBD is individually distinct (28).

We generated fragment ligated inhibitory

peptides (FLIPs) through a strategy called REPLACE (29).
Taking into account the N-terminus FLIP SAR (Chapter 3), a virtual screening of
small molecules was performed by Dr. McInnes.

Specifically, because 4-alkyl

substituted benzoic acids were effective replacements for the N-terminal tripeptide
(LLC), this fragment was used as a template for the identification of compounds
containing

alternatives

phosphothreonine.

for

the

C-terminal

residues,

including

the

critical

Substructure searching for 4-alkylbenzamide derivatives in

commercial libraries and subsequent testing identified one lead molecule, 5881. From
this lead, an SAR program was built, which included the synthesis, characterization, and
analysis of over 40 non-peptidic small molecules. The compounds were synthesized and
characterized by Dr. Sandra Craig in the McInnes lab.

This chapter reports the

biochemical and cellular characterization of compounds from this program.
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4.2. MATERIALS AND METHODS
Fluorescence Polarization Assay
FLIPs and peptides to be tested were dissolved in DMSO (10 mM), and diluted
from 10 nM to 600 µM (maximum of 6% DMSO tolerance in the assay). The PLK1 PBD
(367-603) and PLK3 PBD (335-646) proteins were obtained from BPS Bioscience Inc.
(San Diego, CA); 17 ng

PLK1

and 156 ng PLK3 were used per reaction.

The

fluorescein-tracer phospho-peptides (MAGPMQS[pT]PLNGAKK for PLK1, and
GPLATS[pT]PKNG for PLK3) were used at a final concentration of 10 nM. Incubation
was carried out at room temperature for 45 minutes. Fluorescence was measured using a
DTX 880 plate reader and Multimode Analysis software (Beckman Coulter, Brea, CA).
The polarization values in millipolarization (mP) units were measured at an excitation
wavelength of 488 nm and an emission wavelength of 535 nm. Each data point was
performed in triplicate for every experiment, and experiments were performed at least
three times. An IC50 value for each compound was calculated from linear regression
analysis of the plots.
PLK1 Kinase Inhibition Assay
The CycLex™ Polo-like kinase 1 Assay/Inhibitor Screening Kit was used to
measure catalytic inhibition of peptides and FLIPs (CycLex Co, Ltd., Nagano, Japan).
This ELISA assay measures the catalytic activity of full length PLK1 for a defined
substrate, which is detected by an anti-phospho-threonine antibody (PPT-07) and
peroxidase coupled secondary antibody. Plates pre-coated with a Threonine containing
substrate were incubated with PLK1, kinase buffer containing 7.5 µM ATP (modification
from recommended concentration), in the absence or presence of increasing
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concentration of peptides or FLIP molecules. After incubation, the phosphorylated
substrate resulting from PLK1 kinase activity was detected using the PPT-07 antibody,
and horseradish peroxidase conjugated anti-rabbit IgG antibody. Peroxidase catalyzes
the conversion of the colorless solution to yellow, which was quantified using a DTX 880
plate reader. Absorbance measurements (450 nm) were plotted to calculate activity in
each sample, and % inhibition was calculated in the FLIP containing wells relative to
activity in the absence of inhibitor.
Cell Culture
HeLa cervical cancer cells were obtained from ATCC (Manassas, VA) and were
not authenticated by the authors for this study. Histone H2B GFP-labeled HeLa cells
(HeLa-H2B-GFP) were kindly provided by Dr. Geoffrey Wahl (Gene Expression
Laboratory, Salk Institute) [29], and were confirmed as >95% GFP positive by FACS
(data not shown) but were not otherwise authenticated. Cells were maintained in DMEM
(Invitrogen, Carlsebad, CA) supplemented with 10% FBS or Nu-serum (BD Bioscience,
Franklin Lakes, NJ) and 1% penicillin/streptomycin (Invitrogen) in a humidified
incubator and 5% CO2 at 37°C.
PC3 prostate cancer cells were kindly provided by Dr. Shafiq Khan (Clark Atlanta
University, Atlanta, GA) and were not authenticated by the authors for this study. Cells
were maintained in DMEM (Invitrogen, Carlsebad, CA) supplemented with 10% FBS or
Nu-serum (BD Bioscience, Franklin Lakes, NJ) and 1% penicillin/streptomycin
(Invitrogen) in a humidified incubator and 5% CO2 at 37°C.
A-549 lung cancer cells were obtained from ATCC (Manassas, VA) and were not
authenticated by the authors for this study. Cells were maintained in Hams F-12 1X with
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glutamine (Cellgro, Manassas, VA), and supplemented with 10% FBS or Nu-serum (BD
Bioscience, Franklin Lakes, NJ) and 1% penicillin/streptomycin (Invitrogen) in a
humidified incubator and 5% CO2 at 37°C.
HCT-116 (p53 +/+ and -/-) colon cancer cells were obtained from ATCC
(Manassas, VA) and were not authenticated by the authors for this study. Cells were
maintained in DMEM (Invitrogen, Carlsebad, CA) supplemented with 10% FBS or Nuserum (BD Bioscience, Franklin Lakes, NJ) and 1% penicillin/streptomycin (Invitrogen)
in a humidified incubator and 5% CO2 at 37°C.
Retinal Pigment Epithelial (RPE) cells were kindly provided by Dr. Prasad V.
Jallepalli (Memorial Sloan-Kettering Cancer Center, New York, NY).

Cells were

maintained in 1:1 DMEM/Hams F-12 (Invitrogen, Carlsebad, CA; Cellgro, Manassas,
VA), and supplemented with 10% FBS or Nu-serum (BD Bioscience, Franklin Lakes,
NJ) and 1% penicillin/streptomycin (Invitrogen) in a humidified incubator and 5% CO2 at
37°C.
Cell Viability Assay
Exponentially growing cells were plated in 96- well dishes. Dose response curves
were used to treat cells for 72 hours with FLIPs. Following the three-day treatment, cell
viability

was

measured

using

the

MTT

(3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide) colorimetric assay. Cells were incubated for 3 hours with
MTT allowing viable cells to metabolize the tetrazolium dye to a purple colored solution.
Absorbance measurements (595 nm) were quantified using a DTX 880 plate reader and
IC50 values were generated for FLIPs.
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Serum Starved Synchronization
Cells were synchronized in G1 by serum starvation.

Briefly, exponentially

growing cells were plated overnight. Media (DMEM, 10% FBS, 1% Pen. Strep.) was
then removed and replaced with media containing no FBS. Cells were starved for 72
hours, then treated for 24 hours with small molecule. Following treatment, cells were
harvested and processed for endpoint experimental analysis.
BrdU Labeling/ FACS
Ethanol fixative was removed by centrifugation and the cells were washed with
1mL ice-cold PBS/1%BSA. Cells were denatured by resuspending in 0.2 mg/mL pepsin
in 2N HCl and incubated in 37º C water bath for 15 minutes. Hydrolysis was then
terminated by adding 1 M Tris-Glycine. Cells were then washed with PBS/1%BSA then
the primary anti-BrdU antibody (1:100 dilution in TBFP; 0.5% Tween-20, 1%BSA,
1%FBS, PBS) was added and cells were incubated for 25 minutes in the dark, at room
temperature.

Cells were subsequently washed with PBS/1%BSA then allowed to

incubated for 25 minutes in the secondary fluorescent antibody (1:200 dilution Alexa
Fluor® 488 F(ab’)2 fragment of goat anti-mouse IgG). Cells were washed once more
with PBS/1%BSA and re-suspended in DAPI for 30 minutes before being analyzed by
flow cytometry.
Cell Viability, Apoptosis and Cytotoxicity Assay
The ApoTox Glo TM Triplex Assay (Promega) was used to measure cell viability,
cytotoxicity, and apoptosis in PC3 cells following treatment with 6037. Briefly, PC3
cells were plated at 5,000 – 10,000 cells per well (96 well plate) and attached overnight.
The PBD-inhibitor was then added for a 24 hours treatment, then the results were
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analyzed by fluorescence and luminescence. Cell viability fluorescence was measured at
an excitation wavelength of 400 nm and an emission wavelength of 505 nm, cytotoxicity
fluorescence was measured at an excitation wavelength of 485 nm and an emission
wavelength of 520 nm, and apoptosis was determined with the luminescence
measurement.
4.3. RESULTS
PBD-Inhibitors Bind Potently to the PLK1-PBD and are Moderately Selective
Our previous report identified an N-terminal benzamide capping group with an
alkyl tail as a promising starting structure, and identified a butyl-benzoic containing FLIP
(5827) with low µM affinity for the PLK1 PBD and undetectable binding to PLK3 (29).
We also found that increasing the length of the alkyl tail led to increased binding to PLK1
while maintaining over 2000-fold selectivity (5954) (Chapter 3). Substructure searching
for 4-alkybenzamide derivatives in commercial libraries and subsequent testing identified
one lead molecule, 5881. From this lead, the structure activity relationship (SAR) of
more than forty small molecules was analyzed. The total of these compounds can be
found in Table 4.1. Specifically, we analyzed compound binding to PLK1 (discussed
first) and PLK3 (discussed second) in vitro. We also measured ATP inhibition and
analyzed compound activity in cancer cells.
Structure Activity Relationship of C-capping group on Benzamide Small Molecules
Compound 5880 (butyl-benzamide) did not bind to the PBD of PLK1, however
5905 (pentyl-benzamide) bound to the PLK1 PBD with weak affinity (IC50 = 223.6 ±
4.88 µM). When the alkyl tail length was increased from pentyl to hexyl (5881), PLK1
binding increased 12-fold (IC50 = 18.4 ± 5.3 µM). This result is consistent with FLIP
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SAR which also demonstrated that increasing the length of the alkyl tail improved PLK1
binding (Chapter 3). 5881 also binds to PLK3 (IC50 = 18.04 ± 5.18 µM), but remains 5fold selective for PLK1. We observed an increase in binding for PLK1 by further
lengthening (octyl) the alkyl tail (5912) (IC50 = 11.27 ± 2.7 µM). Selectivity was also
marginally improved (PLK3 IC50 = 15.48 ± 0.01 µM), relative to 5881 (compare 5881
fold selectivity = 5, to 5912 fold selectivity = 6.9). We continued to lengthen the alkyl
tail even further, to determine if PLK1 binding would be further increased (6037).
Increasing the carbon chain to 12 carbons resulted in the generation of our least selective
small molecule (PLK1 IC50 = 5.97 ± 0.38; PLK3 IC50 = 1.99 ±0.69; Fold selectivity =
1.6) (Table 4.2)
Structure Activity Relationship of C-capping group on Hexyl-Benzamide Small Molecules
Several derivatives of 5881 were synthesized and an analysis of the SAR of
substituents on the C-terminal replacement was analyzed (Table 4.3). When the position
of the carboxylic acid was moved from ortho to meta (from the amide), we observed a
loss of PLK1 binding affinity (5903 IC50 = 129.8± 3.6 µM) with minimal PLK1
selectivity (PLK3 IC50 = 43.62 ± 1.69 µM, Fold selectivity =1.6). No binding was
observed with a sulfonamide phospho-mimic (5908), or when using a phosphate (5940)
or hydroxyl (5943) group (Table 4.3). Interestingly, when a methyl group was positioned
meta to the carboxylic acid (5924), we observed PLK3 PBD binding (IC50 = 24.5 µM),
but no binding to PLK1.
Structure Activity Relationship of C-capping Group on Octyl-Benzamide Small Molecules
Several derivatives of 5912 were synthesized and an analysis of the SAR of
substituents on the C-terminal replacement was analyzed.
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As expected due to the

putative contribution of the negatively charged carboxylate group, PLK1 binding was lost
when the carboxylic acid was converted to an ethyl ester (5914; IC50 = >600 µM) (Table
4.4A). This compound was used as a negative control for cellular analysis. When
compound 5932 (Table 4.4A) was synthesized containing a fluorine ortho to the
carboxylic acid, PLK1 PBD binding affinity did not improve (relative to 5912), nor was
PLK1 selectivity increased.

When fluorine was added at both the ortho and para

positions (5938) (Table 4.4B) PLK1 PBD binding decreased (IC50 = 30.6 ± 3.2 µM) as
did PLK3 binding (IC50 = 39.7 µM). Improved PLK1 binding (IC50 = 2.16 ± 0.01 µM)
and selectivity (PLK3 IC50 = 7.68 ± 2.41 µM, Fold Selectivity = 18) was observed upon
addition of a methyl group meta to the carboxylic acid (5915, Table 4.4A).

It is

important to note that the only difference between this compound and 5924 (hexyl) is the
length of the alkyl tail. Increasing the length from hexyl (5924, Table 4.3) to octyl
(5915) dramatically improved PLK1 binding and produced the most selective compound
in this series (Table 4.4A). When the methyl group is positioned para to the carboxylic
acid (5937, Table 4.4A), PLK1 selectivity decreased 2-fold relative to 5915 (compare
5915 fold selectivity = 18 with 5937 fold selectivity = 9.3). The compound containing a
methoxy group positioned meta to the carboxylic acid (5935) was 11.5-fold selective for
PLK1, binding with an IC50 = 5.89 ± 1.25 µM (Table 4.4B). 5939 contains a nitro group
ortho to the carboxylic acid (Table 4.4B). It is 8-fold selective for PLK1, binding to the
PLK1 PBD with an IC50 = 6.05 ± 1.9 µM (PLK3 PBD IC50 = 9.96 ± 1.52 µM).
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Structure Activity Relationship of C-capping Group with Flexible Octyl Benzamine Small
Molecules
Small molecules containing a flexible alkyl benzamine structure were also
synthesized to explore the SAR of compounds with less rigidity with respect to the two
benzyl rings (Table 4.5). Accordingly, 5953 was synthesized with a methylamino instead
of the amide linkage found in 5912. Binding to PLK1 was slightly improved (5953 IC50
= 9.57 ± 2.03), relative to 5912. Next, 5961 contains the methylamino linker and a
methyl group meta to the carboxylic acid – the same substitution at the R4 position as
5915. Binding of 5961 to the PLK1 PBD was undetectable, but it did have weak affinity
for the PLK3 PBD (IC50 = 156.7 µM) (Table 4.5). Positioning of a methyl group para to
the carboxylic acid (5971), resulted in improved PLK1 binding (IC50 = 21.69 ± 2.8 µM)
relative to 5961. This represents more than 27-fold increase in PLK1 binding relative to
5961, however there was a 2-fold loss in binding relative to 5953 (Table 4.5).
PBD- Inhibitors reduce the catalytic activity of PLK1
The ability of the most promising compounds to inhibit the catalytic activity of
full length PLK1 was investigated using an in vitro ELISA based PLK1 kinase assay.
The PBD-based PLK1 inhibitors (5912, 5932, and 5915) inhibited the catalytic activity of
the protein (IC50 = 42.3 µM, 48.9 µM, and 24.3 µM, respectively) (Table 4.4A). The
results from this assay were an important confirmation of compound binding to PLK1 in
an orthogonal assay.
PBD-Inhibitors decrease Cancer Cell Proliferation
Our most promising compounds were tested in multiple cancer cell lines,
including HeLa cervical cancer cells, PTEN deficient prostate cancer (PC3) cells, and
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Kras mutant lung cancer (A-549) cells (Table 4.6). Each of these cancer cells lines were
sensitive to the lead PBD-inhibitors in a cell viability assay with the A-549 lung cancer
cells being the most sensitive overall. This is consistent with literature stating a synthetic
lethal interaction exists with PLK1 mutant Ras cancer cells (13). A synthetic lethal
interaction has also been demonstrated between PLK1 and PTEN deficient prostate
cancer cells (14, 15). We also observed a differential sensitivity depending on p53 status.
Specifically, a greater anti-proliferative effect was observed on p53 null HCT 116 colon
cancer cells compared to p53 proficient HCT 116 cells (Table 4.6).
Targeting the Polo-Box Domain of PLK1 circumvents resistance to catalytic inhibitors in
cells expressing mutant (C67V) PLK1
Burkard et al (2012) demonstrated that a single point mutation within the catalytic
domain of PLK1 conferred resistance to ATP-based inhibitors while retaining full
catalytic activity (27). We obtained the Retinal Pigment Epithelial (RPE) cells generated
by the Burkard group and confirmed the resistant phenotype by cell viability assay
(Figure 4.1). Wild Type (WT) RPE cells are sensitive to BI-2536 (IC50 = 21.2 nM) while
mutant RPE cells are dramatically resistant to BI-2536 (> 2.5 µM) (Chapter 3). We
found that non-peptidic PBD-inhibitors were able to circumvent the resistance observed
by ATP-based inhibitors using the RPE cell line generated by the Burkard group. Cells
containing wild type and mutant (C67V) PLK1 were sensitive to our lead PBD-inhibitors
(5912 and 5932) while C67V mutant cells were resistant to BI-2536 – an ATPcompetitive PLK1 inhibitor (Figure 4.1).
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Cell cycle analysis reveals dose-dependent phenotype
Our PLK1 PBD-inhibitors were analyzed further by cell cycle analysis to
determine if PBD-inhibition induces a similar phenotype as ATP-inhibition (G2/M arrest)
(Figure 4.2). PC3 cells were synchronized in G1 by serum starvation then treated for 24
hours with PBD inhibitor (see methods). At a concentration of 5 µM, 5912 shows
moderate (13% increase relative to control) increase in G2/M population, suggesting
PLK1 is being inhibited (Figure 4.3). This result is modest when compared to those
obtained using an ATP-competitive inhibitor (BI-2536), which shows nearly 80% of cells
accumulate in G2/M. A higher concentration of 5912 (15 µM) results in a phenotype that
suggests other targets are being engaged (Figure 4.2). 5912 shows S phase delay (most
likely entry into S phase) (Figure 4.2 and 4.3) – implicating PLK3 inhibition at 15 µM;
whereas 5915 and 5935 shows G1 delay (delayed exit) or arrest (cells no longer cycling)
at 15 µM which could imply PLK2 or PLK3 inhibition. To quantify the percentage of
cells actively proliferating (synthesizing their DNA) we carried out Bromodeoxyuridine
(BrdU) pulse labeling and analyzed these by flow cytometry. Results showed that 28.3%
of cells are replicating their DNA when treated with 5 µM 5915, however, cells are
arrested in G1 (BrdU + = 3.6%) following treatment with 15 µM 5915.
After treating PC3 cells with 6037 – our least selective inhibitor (Fold Selectivity
= 1.6) – we observed G1 accumulation at both the lower (5 µM) and higher (15 µM) dose
(Figure 4.4). Upon low dose (5 µM) treatment, BrdU labeling showed that 75.7% of the
cells are replicating their DNA. This suggests that the lower dose observations result
from either a delay of cells exiting G1 or delayed progression through S phase, as
opposed to an S-phase arrest. Like 5915, a G1 arrest is observed following the higher
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dose (15 µM) treatment with 6037 (%G1 = 31.2; BrdU + = 1.9%). Interestingly, 40% of
the cells were in sub-G1, indicating death is occurring at the higher (15 µM) dose (Figure
4.4). Cell death and cytotoxicity analysis showed that 6037 induces apoptosis at 15.0 ±
5.6 µM in PC3 cells (Figure 4.5).
4.4. DISCUSSION
Development of small molecules that bind to the PBD of PLK1 and inhibit catalytic
function
Through the use of REPLACE we were able to successfully develop non-peptidic
small molecules that bind to the PBD of PLK1. N-terminal SAR developed from the
study of peptides and FLIPs in Chapter 3 was useful for the discovery and optimization
of our small molecule PBD-inhibitors. The development of a lead series of compounds
was a big leap forward. An in vitro catalytic inhibition assay showed that in addition to
PBD binding, our small molecules also inhibit the catalytic activity of the protein. These
results from an orthogonal assay provide reassurance that the PBD binding observed in
the FP assay for the small molecules accurately reflects compound activity for PLK1
despite only using the PBD fragment in the FP Assay.
Although these first generation compounds are modestly selective for PLK1, they
provide a good starting point for the development of more selective compounds in the
future. FLIP results indicate that the C-terminal amino acids contribute to selectivity
within the PLK1 binding pocket (Chapter 3). Additional analysis of FLIP C-terminal
SAR will allow the application of those parameters in a compound library search, and
will lead to the development of more selective second generation small molecules.
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Small molecule SAR remained consistent with results observed in Chapter 3, in
that lengthening the alkyl tail resulted in increased binding to PLK1 (Table 4.2). The
PBD is a phospho-peptide binding motif, so it recognizes and binds to the phosphorylated
serines and threonines of its substrates. The carboxylic acid serves as a phosphate mimic
to which both the PLK1 and PLK3 PBD bound (5912) (PLK1 IC50 = 11.27 ± 2.7 µM,
PLK3 IC50 = 15.48 ± 0.01 µM). Although 5912 bound to the PLK3 PBD it remained 7fold selective for PLK1. A fluorine group was positioned ortho to the carboxylic acid
(5932) to make the carboxylic more phosphate like (and increase the bulk of the negative
charge). The fluorine substituent did not improve PLK1 binding or selectivity. Octylbenzamide SAR shows methyl group substituents (meta or para to the carboxylic acid)
(5915 and 5937) provided the greatest contribution to PLK1 binding and selectivity in
this series. The methyl group positioned meta to the carboxylic acid (5915) makes the
greatest contribution to PLK1 selectivity (Fold selectivity = 18), however, PLK1 binding
and selectivity was completely lost when the octyl benzamide was replaced with an octyl
benzamine (5961). Although PLK3 PBD binding also decreased with the flexible amine,
binding was still detectable, resulting in a PLK3 selective compound. The same trend
was observed (loss in PLK1 PBD binding) when comparing 5937 (octyl benzamide with
methyl group para to the carboxylic acid) with 5971 (octyl benzamine with methyl group
para to the carboxylic acid). Binding was not completely lost, like we observed with the
methyl group in the meta position, but there was 5.5-fold decrease in PLK1 PBD binding
with loss of rigidity when the methyl is in the para position (compare 5937 with 5971).
This suggests an important conformational role in that the loss of PLK1 selectivity
observed with 5961 and 5971 may result from additional flexibility which makes PLK1
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PBD binding entropically unfavorable, and PLK3 PBD binding favorable. In addition,
the methyl group is a hydrophobic residue that could be removing water from the proteins
binding site.

This could also explain its contribution to PLK1 PBD binding and

selectivity
Cancer cells are sensitive to PBD-inhibitors
HeLa, PC3, A-549, and HCT-116 cancer cells were sensitive to our PBDinhibitors. Cell viability decreased in a dose-dependent manner in all cell lines, but A549 (Kras mutant) lung cancer cells were most sensitive. This supports research findings
showing a synthetic lethal interaction exist between cells expressing Kras mutations and
PLK1. Synthetic lethality also exist between PTEN deficient prostate cancer cells and
PLK1. However, we did not rigorously test this possibility in isogenic PTEN proficient
and deficient prostate cancer cell lines (15). The literature also reports a sensitivity of
p53 defective cancer cells to PLK1 inhibition (30). p53 is a tumor suppressor that is
frequently mutated in cancer (31). p53 and PLK1 negatively regulate one another (32).
Interestingly, when testing our compounds in an isogenic colon cancer cell line (HCT116), we found that p53 null cells were more sensitive than p53 wild type (WT) cells.
Sur et al (2009) showed that the viability of stressed cells was dependent on PLK1 when
those cells lack wild type (WT) p53. Specifically, it was shown that a G1 arrest was
induced in cells expressing WT p53 upon treating with ionizing radiation. This G1 arrest
protected the cells from the toxic effects of BI-2336 – a PLK1 inhibitor – while cells
expressing mutant p53 did not arrest in G1 and were thus sensitized to BI-2536 (33).
They demonstrated that combining PLK1 inhibitors with ionizing radiation can induce a
p53 dependent G1 cell arrest that will protect normal cells from the toxic effects of PLK
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inhibition (33).

The observed p53 dependent effect with our small molecules has

encouraging clinical implications and future work could explore the potential protective
effects of ionizing radiation (or other therapies that induce p53-dependent G1 arrest) with
PBD inhibitors.
Cell Cycle Analysis Suggest Dose-Dependent Phenotype
Treating PC3 cells with 5912 at a lower dose leads to an accumulation of cells in
G2/M. This phenotype is consistent with ATP-competitive PLK1 inhibition. At a higher
dose, we observe a G1 arrest. One of our compounds (6037) induced a G1 arrest at all
doses examined.

6037 is our least selective compound in this series, with almost

equipotent binding to PLK1 and PLK3. It has been shown that depleting PLK3 by
siRNA results in a G1 arrest, and the authors concluded that PLK3 is required for entry
into S phase (34). We therefore speculate that 6037, and other compounds in the series at
higher doses, might be inhibiting PLK3, which would invoke a G1 arrest and preclude the
inhibition of PLK1 in mitosis. However, additional investigation is needed to confirm
that PLK3 is being targeted since there are other possible explanations.
Cell cycle analysis confirmed that cells were synthesizing their DNA when treated with
the lower (5 µM) dose of 6037, suggesting the compound induces a G1 delay. However,
at the higher dose (15 µM) cells were arrested in G1 and began to undergo apoptotic cell
death. Taken together the cellular analysis supports the FP data showing low PLK1
selectivity for 6037.
There is approximately 30% sequence homology between the PBD’s of PLK1 and
PLK2, however, these proteins have opposite functions in tumor development (35).
PLK2 expression and activity has been shown to increase as cells enter S phase (36, 37).
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We observe a delay in cell cycle progression through S phase when treating cells with 15
µM dose of our PBD inhibitors. It is possible that we could be targeting PLK2 when
treating cancer cells at a higher dose. Notably, one other possibility is that targeting the
PBD of PLK1 (as opposed to catalytic inhibition) in cancer cells with elevated PLK1
expression in interphase might produce a novel phenotype.
PBD-inhibitors circumvent resistance to ATP-competitive inhibitors in cells expressing
mutant PLK1
A chemical genetics study from 2012 has shown that cells containing a point
mutation within the ATP-binding site of PLK1 (C67V) are resistant to several structurally
unrelated ATP-inhibitors.

In addition to being resistant, these cells also retain the

catalytic function of the PLK1 protein (27). Although this mutation has not yet been
reported clinically, the likelihood of such a mutation occurring is possible, and would
render ATP-inhibitors ineffective in a relapsed tumor. Our PBD inhibitors were equally
effective in cells expressing the C67V PLK1 mutation as they were in cells expressing
the wild type form or the protein.
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TABLES
Table 4.1 SAR of 40 PBD Inhibitors. Compounds are organized numerically and the
IC50 values for PLK1 and PLK3 are indicated. ND indicates values that were Not
Determined.
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Table 4.2 Biochemical analysis of C-capping group on benzamide small molecules.
Compound structure, binding affinities, PLK1 selectivity, and catalytic inhibition are
indicated.
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Table 4.3 Biochemical analysis of C-capping group on hexyl benzamide small
molecules. Compound structure, binding affinities, and PLK1 selectivity are indicated.
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Table 4.4 Biochemical analysis of C-capping group with Rigid Octyl Benzamide.
Compound structure, binding affinities, PLK1 selectivity, and catalytic inhibition are
indicated.
A.

B.
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Table 4.5 Biochemical analysis of C-capping group with Flexible Octyl Benzamine.
Compound structure, binding affinities, and PLK1 selectivity are indicated.

Table 4.6 Cancer cell viability analysis of small molecules. Numbers represent IC50
values generated from three independent 72 hour cell proliferation (MTT) assays.
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FIGURES

Figure 4.1 Retinal Pigment Epitelial (RPE) cells are sensitive to 5912 and 5932. RPE
cells expressing C67V PLK1 are resistant to BI-2536, an ATP-competitive inhibitor.
Dose response curves generated from three cell proliferation assays. Standard Deviation
(SD) used to generate error bars.
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Figure 4.2 Cell cycle analysis of PBD inhibitors in prostate cancer (PC3) cells. Cells
were synchronized in G1 by 72 hr serum starvation, followed by 24 hr treatment with
PBD inhibitor. DNA content was averaged across three or more independent
experiments and standard deviation was calculated to generate error bars.
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Figure 4.3 Cell cycle analysis of 5912 in prostate cancer (PC3) cells. Cells were
synchronized in G1 by 72 hr serum starvation, followed by 24 hr treatment with PBD
inhibitor. DNA content was averaged across three or more independent experiments and
standard deviation was calculated to generate error bars.
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Figure 4.4 Cell cycle analysis of 6037 in prostate cancer (PC3) cells. Cells were
synchronized in G1 by 72 hr serum starvation, followed by 24 hr treatment with PBD
inhibitor. DNA content was averaged across two independent experiments and standard
deviation was calculated to generate error bars.
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Figure 4.5 Viability, cytotoxicity, and apoptotic analysis of 6037 in PC3 cells. Cells
were analyzed using the ApoTox-Glo TM Triplex Assay (Promega). Dose-response
curves were measured in triplicate. Viable Concentration = 15.6 ± 3.4 µM, Apoptosis
Concentration = 15.0 ± 5.6 µM
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CHAPTER FIVE
CONCLUSIONS AND FUTURE DIRECTIONS
This study builds upon the work published by our group in 2012 (1) and further
validates our approach to developing PBD targeted PLK1 inhibitors by the REPLACE
(Replacement with Partial Ligand Alternatives through Computational Enrichment)
method. This structure guided drug discovery process was further validated by the
successful development of potent and selective peptide and FLIP PBD inhibitors. In
addition, synthesis of the first generation of small molecules represents an important leap
forward, and provides a good starting point for the development of more selective
compounds in the future.

This chapter will provide suggestions for experimental

approaches to move this project forward.
5.1 CHAPTER TWO SUMMARY
In chapter two we demonstrate the importance of developing a fluorescent
polarization (FP) assay that will accurately measure the binding of our peptides,
Fragment Ligated Inhibitory Peptides (FLIPs), and compounds to the PBD of PLK1 and
PLK3. To accurately measure binding the assay conditions must be properly optimized
and routinely confirmed.

We were able to determine the tracer concentration that

provides adequate signal above background without saturating the detection limits of the
machine. Both the PLK1 and PLK3 FP assays required a 10 nM tracer concentration.
We also identified the Polo-Box Domain (PBD) concentration at which 90% of the tracer
was bound. Proper assay development has allowed for the continued use of the PLK1 FP
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assay as our primary screen, and the PLK3 FP assay as a counter screen to detect
compound binding.
In addition to continued quality control processes, future studies should include
optimizing assay conditions with the full length PLK1 and PLK3 protein. Doing so
would more accurately reflect compound binding in a system, in that cells express the full
length protein and not the PBD alone. Additionally, an FP assay could be developed for
PLK2 and PLK4 as additional counter screening tools.
Future studies should also include the use of a more stable fluorophore for the
tracer peptide. For example, BODIPY dyes remain in the excited state longer than
fluorescein – the dye we currently use. This results in an increased sensitivity to binding
interactions over a broader molecular weight range (2). The use of red-shifted probes are
also recommended to reduce fluorescence interference from test compounds (2).
5.2 CHAPTER THREE SUMMARY
Chapter three demonstrates the successful development of highly potent and
selective peptide and FLIP PBD inhibitors through the use of REPLACE. By truncating
the N-terminal amino acids of known PLK1 substrates and replacing them with small
molecular drug-like fragments we were able to exploit the PBD binding pocket and
investigate the Structure Activity Relationship (SAR) of a series of compounds
containing alkyl benzamide N-terminal replacements. The peptides and FLIPs bound
both potently and selectively to PLK1, providing the basis for the development of nonpeptidic small molecules (discussed in Chapter 4). FLIPs were also able to inhibit the
catalytic activity of PLK1 in vitro, and cause a decrease in prostate (PC3), cervical
(HeLa), and lung (A-549) cancer cell proliferation. Both wild type and mutant (C67V)
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PLK1 Retinal Pigment Epithelial (RPE) cells were sensitive to 5996 and 6026 RPE cells
expressing mutant PLK1 were resistant to ATP-based PLK1 inhibitors.
The results demonstrated that the N-terminal amino acids contributed to
compound potency while the C-terminal amino acids contributed to compound selectivity
(Table 3.1). This was further demonstrated from the SAR of the octyl-benzamide FLIPs
(Table 3.3) in which C-terminal amino acids were analyzed (5988, 5996, 6026). Future
studies should include a more in depth study of C-terminal amino acid SAR with the
octyl-benzamide N-capping group. Doing so will provide valuable information about the
PLK1 PBD binding pocket. That information can then be used to generate a drug-like
molecular fragment that will mimic the intermolecular contributions of the amino acid
sequence that produces the most selective FLIP.
Peptides are typically not useful as drugs because they get degraded or cleaved
before reaching their target. Despite the peptidic nature of our compounds, we were able
to detect cellular activity (Table 3.4) in HeLa, PC3, and A-549 cancer cells. While this
was encouraging, the calculated IC50 values were in the higher microMolar range. This is
due, in part, to the degradation that occurs with all peptides. A drug delivery system
should be used in the future, for a more accurate IC50 measurement in cells because it will
ensure that the compound reaches its target without degrading. I expect that the cellular
IC50 values will decrease as a result of the compound reaching its target. A drug delivery
system will also allow additional mechanistic and phenotypic questions about PBDinhibition to be answered.

We cannot assume that PBD inhibition will result in

phenotypes consistent with ATP-inhibition. To determine similarities or differences with
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PBD inhibition, future studies should include immunofluorescence microscopy, cell cycle
analysis, and western blotting
Our efforts to carry out PLK1 localization studies were unsuccessful due to
inconsistencies with our drug delivery system. Immunofluorescence microscopy will
allow for the visualization of aberrant mitotic phenotypes (i.e. PLK1 localization, spindle
pole formation, and the number of centrosomes).
Future studies should build upon the cell cycle analysis results for 6026 (200 µM)
(Table 3.6, Figure 3.1) and use a mitotic marker to identify whether cells are in G2 or
Mitosis by flow cytometry. This will allow for a better understanding of the affect FLIPs
have on the cell cycle, and it will provide a starting point for investigation into
mechanistic studies. If cells are in G2, it can be assumed that PBD inhibition affects
PLK1’s role in mitotic entry, therefore, further investigation into CDK1 and cyclin B
should take place. Recall that PLK1 phosphorylates and activates the phosphatase
Cdc25C in G2 (Chapter 1). Cdc25C then dephosphorylates CDK1, allowing it to form a
complex with cyclin B, thereby initiating mitotic entry. If cells are in mitosis, mitotic
phenotypes should be further explored.
Efforts to determine apoptotic induction by 6026 with flow cytometry were also
unsuccessful. Asynchronous HeLa cells were treated for 24 and 48 hours with 250 µM
of 6026. We failed to see an induction of apoptosis, but additional analysis using a drug
delivery system is needed (Table 5.1). Future work could also explore apoptosis by
western blot analysis, probing for cleaved PARP, or caspase 3. Western blot analysis
could also be used to directly measure PLK inhibition by probing for PLK1 and its
substrates after treating cells with FLIPs.
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Building upon the cell proliferation data is also an important initial step in
determining the mechanism by which cells are dying when treated with FLIPs (Table
3.4).
Lastly, cells expressing mutant (C67V) PLK1 were sensitive to our PBD
inhibitors (Table 3.5). Future studies should include establishing a cancer cell line
expressing the C67V mutation and cell lines expressing mutation(s) within the PBD.
This will be discussed further in section 5.3.
5.3 CHAPTER FOUR SUMMARY
Chapter 4 discusses the development of 40 small molecules synthesized by the
McInnes group (Dr. Sandra Craig). These compounds bind to the PLK1 PBD and
inhibits the catalytic activity of the protein (Table 4.1). Our small molecules also cause a
decrease in cancer cell proliferation (Table 4.6), and 5912 and 5932 where shown to
circumvent the resistance observed in cells expressing mutant (C67V) PLK1 when
treated with catalytic inhibitors (Figure 4.1). Lastly, our results suggests PLK1 is being
targeted when treating PC3 cells with a lower dose (5 µM), and our compounds are
targeting a different protein (possibly PLK3) when treating with a higher dose (15 µM).
Our least selective compound (6037) has off target effects at both the lower and higher
doses.
N-terminus FLIP SAR was used to identify replacements for the C-terminus
amino acid residues in a virtual compound library screen. This was done in parallel with
the development of the FLIPs. We developed a lead molecule (5881) and went on to
generate forty small molecules that have modest PLK1 selectivity. Future studies should
take into account the C-terminus SAR when carrying out the next compound library
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screen to develop second generation small molecules.

Doing so could provide

replacements that result in a lead molecule with increased PLK1 selectivity.
The C67V RPE cells were sensitive to our non-peptidic compounds while
remaining resistant to BI-2536 (ATP- inhibitor) (Figure 4.1). We established a transient
resistance model to test the efficacy of our PBD based inhibitors. We obtained GFPfusion expression constructs for wild-type PLK1 and PLK3 (a gift from Dr. Wei Dai,
New York University School of Medicine, NY). The PLK1 construct was transfected
into PC3 cells to ensure cancer cells would take up the plasmid (Figure 5.1). Once
confirmed the C67V mutant PLK1 construct was created by site-directed mutagenesis
(Figure 5.2). We confirmed the mutation by sequencing. Transient transfections of GFP
only (control), WT-PLK1, and C67V PLK1 into HeLa cells were carried out (Figure 5.3)
by electroporation. We were able to confirm the results of Burkard et al. (3) in our
system, showing that HeLa cells transiently overexpressing the C67V mutant PLK1 are
more resistant than cells overexpressing WT-PLK1, as evidenced by the number of
colonies in the respective wells treated with 1 nM BI-2536 (Figure 5.3).
Future studies should build upon this work and establish an isogenic cancer cell
line stably expressing mutant PLK1. Our efforts to establish a stable cancer cell line
were unsuccessful. We found that cells expressed our GFP fusion constructs for 72 – 96
hours, with expression peaking at 48 hours (Figure 5.4). This was observed with HeLa,
PC3, DU-145, A-549, and Daudi cancer cells (not shown). After 48 hours, there was a
decrease in plasmid expression (as evidenced by GFP) in all cell lines tested. Decreased
expression after 48 hours was also observed when cells were placed under selection and
we were unsuccessful in isolating any stable colonies.
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Future work should include knocking out endogenous PLK1 and adding back the
PLK1 plasmid constructs, as described in Burkard et al, (2012) (3). This would allow for
mechanistic investigation of our small molecules in a cancer cell resistance model.
It would be interesting to determine if a mutation within the Polo-box Domain
would 1) allow the protein to retain its substrate specificity and catalytic function while,
2) generating resistance to PBD-inhibition. This is important because drug resistance is
always a concern with cancer therapeutics because cancer cells will generate mutations to
survive. Potential mutations could be determined by exposing cancer cell lines to a low
dose of our PBD inhibitors over time.

The DNA of any surviving cells could be

sequenced and then compared to untreated cells. This would allow for the discovery of
any acquired genetic mutations as a result of PBD inhibition.
Future studies should also include a direct measure of PLK1 inhibition in cells by
western blot analysis. Probing for PLK1 and its substrates will directly confirm that
PLK1 is being targeted in cancer cells when treated with our small molecules.
Because of the concern with resistance developing as a result of single agent
therapy, future studies could also investigate the potential for a synergistic affect when
treating cancer cells with PBD and ATP-based inhibitors. It will be important to take the
next step and carry out in vivo studies once there is a compound that is both potent and
selective in vitro and in cells.
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TABLES
Table 5.1 HeLa cell death analysis following treatment with 6026. HeLa cells were
treated for 24 and 48 hours with 250 µM 6026. BI-2536 is an ATP-inhibitor of PLK1
and serves as the positive control. Values represent cell percentages.
Untreated
Necrotic
Late Apoptotic
Normal
Early apoptotic

4.3
1.3
92.7
1.7

BI-2536
48hr
15.6
24.3
37.5
22.6
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6026
24hr
9.1
2.7
86.4
1.9

6026
48hr
11.9
3.4
81.2
3.5

FIGURES

Figure 5.1 Western Blot analysis of GFP and GFP-PLK1 fusion construct
expression in PC3 cells. The lower band shows endogenous PLK1 expressed in PC3
cells. The left lane shows extracts from cells electroporated with the GFP only expression
construct. The right lane shows that the GFP-labeled PLK1 is expressed in cells
electroporated with the expression construct. The data shows that the expression
construct works and that PC3 cells are capable of over-expressing PLK1.

Figure 5.2 Primers used for C67V site directed mutagenesis. These primers generated
the C67V mutation in the GFP-PLK1 fusion construct. Mutation was confirmed by
sequencing
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Figure 5.3 C67V PLK1 resistance model in HeLa cells.
expressing mutant PLK1 are resistant to BI-2536.

HeLa cells transiently

Figure 5.4 Percentage of HeLa cells expressing the GFP-fusion constructs.
Expression 24 hours following electroporation. Expression peaked 48 hours after
electroporation for all constructs.
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